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ABSTRACT OF THE DISSERTATION 
STRAIN PROMOTED CLICK CHEMISTRY OF 8-AZIDOPURINE AND 5-
AZIDOPYRIMIDINE NUCLEOSIDES AND NUCLEOTIDES WITH 
CYCLOOCTYNES AND APPLICATIONS TO LIVING CELL IMAGING 
by 
Jessica Zayas 
Florida International University, 2015 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
The strain promoted azide alkyne cycloaddition (SPAAC) of azido nucleobase 
modified nucleosides and nucleotides with cyclooctynes to give fluorescent triazoles has 
been relatively unexplored. Thus, SPAAC between azido-nucleobases and various 
cyclooctynes in aqueous solution at ambient temperature resulted in the efficient 
formation (3 min - 2 h) of triazole products with inherent fluorescent properties. The 2- 
and 8-azidoadenine nucleosides reacted with fused cyclopropyl cyclooctyne, 
dibenzylcyclooctyne or monofluorocyclooctyne to produce click products functionalized 
with hydroxyl, amino, N-hydroxysuccinimide, or biotin moieties. The previously 
unexplored 5-azidouridine and labile 5-azido-2'-deoxyuridine were similarly converted to 
the analogous triazole products in quantitative yields in less than 5 minutes. The 8-azido-
ATP quantitatively afforded the triazole product with fused cyclopropyl cyclooctyne (3 
h). Addition of a triazole ring at the 2 or 8 position of adenine or 5-position of uracil 
induces fluorescent properties which were used for direct imaging with fluorescent 
microscopy in MCF-7 cancer cells without the need for traditional fluorogenic reporters. 
ix 
 
Fluorescent lifetime imaging microscopy of the click adducts in live cells were used to 
determine the lifetime of each fluorophore in the cellular nuclei demonstrating the 
potential utility of the synthesized triazole adducts for dynamic measuring and tracking of 
events inside single living cancer cells.  
The SPAAC methodology developed has also been applied to study the cellular 
targets in protozoal parasite, Trichomonas vaginalis and bacteria, Pseudomonas 
aeruginosa. The 9-(2-deoxy-2-fluoro-β,D-arabino-furanosyl)adenine (arabino-F-Ado) 
was modified with an azido moiety at the C8 position for use in click chemistry. Tagging 
and subcellular localization studies using azido modified arabino-F-Ado could provide 
insight into the mechanism of action of arabino-F-Ado.  
An activated analogue of S-adenosyl-L-methionine (SAM) with an EnYn group on 
the sulfur instead of a methyl group was prepared to study the transfer of the methyl 
group from SAM. I found that the EnYn group was transferred from SAM to a guanosine 
on tRNA by methytransferase Trm1. Thus, AdoEnYn is a competitive inhibitor of SAM 
and can be incorporated into tRNA in place of SAM.  
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1. Introduction 
1.1 Nucleosides for Medicinal Applications 
Nucleosides and nucleotides make up the basic building blocks of DNA and 
RNA. They are involved in many important cellular process including cell signaling, 
enzyme regulation and metabolism.1 As such, nucleoside and nucleotide derivatives have 
been developed to mimic their parent compounds and thus are able to exploit cellular 
metabolism by being incorporated into DNA and RNA.2 Nucleoside and nucleotide 
analogues enter cells using nucleoside transporters;3-4 once inside they interact with and 
inhibit important enzymes including polymerases, kinases and ribonucleotide reductase.1 
After incorporation and phosphorylation, the nucleoside analogues are typically able to 
inhibit cellular division, viral replication and act as chain terminators causing cellular 
apoptosis and potential therapeutic benefits.5  
1.1.1 FDA Approved Nucleoside Based Anticancer and Antiviral Agents 
The 6-mercaptopurine and acyclovir, two important antiviral agents, were first 
developed by Elion and Hitchings.6-7 The first antiviral nucleoside analogue approved by 
the FDA was edoxudine in 1969, but it is no longer used in the clinic. Since then work by 
De Clerq and Holy has allowed the development and eventual FDA approval of several 
landmark nucleoside based drugs.8-9 Currently, there are over 25 FDA approved 
nucleoside and nucleotide analogues that are used as antiviral or anticancer agents and 
several more in the clinical trial stage, Table 1.2 Despite the widespread availability of 
anticancer and antiviral nucleoside analogues, the development of derivatives with 
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improved properties is imperative in order to overcome metabolic resistance,10 poor oral 
bioavailability,11 long term toxicity12 and variability from patient to patient.1       
Drug Parent Category Year 
5-aza-2'-deoxycytidine (Decitabine) 2′-Deoxycytidine 2006 
O6-methylarabinofuranosyl guanine (Nelarabine) Guanosine  2005 
5-aza-cytidine (Azacitidine) 2′-Deoxyadenosine 2004 
2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine (Clofarabine) Cytidine 2004 
N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Capecitabine) Cytidine 1998 
2,2-difluoro-2'-deoxycytidine (Gemcitabine) 2′-Deoxycytidine 1996 
2-chloro-2'-deoxyadenosine (Cladribine) 2′-Deoxyadenosine 1992 
2'-deoxycoformycin (Pentostatin) Adenosine 1991 
Arabinofuranosyl-2-fluoroadenine (Fludarabine) Purine analogue 1991 
5-fluoro-2'-deoxyuridine (Floxuridine) 2′-Deoxyuridine 1970 
Arabinofuranosylcytosine (Cytarabine) Cytidine 1969 
6-thioguanine (Lanvis) Guanine 1966 
5-fluorouracil (Adrucil) Uracil 1962 
6-mercaptopurine (Purinethol) Purine 1953 
 
Table 1. FDA Approved Anticancer nucleoside analogues 
Cytarabine, 1-β-D-arabinofuranosylcytosine, was approved in 1969 by the FDA 
for the treatment of white blood cell cancers. It contributes to the cure of acute myeloid 
leukemia and non-Hodgkin lymphoma13 in about 30% of cancer patients.  Cytarabine 
also possesses potent antiviral activity and has been long used to treat herpes infections;14 
however, it causes severe side effects including bone marrow suppression and is toxic at 
higher dosages.10, 15   
Several adenosine analogues display potent antiviral and anticancer activities 
including 8-chloro and 8-aminoadenosine16-17 which decrease the intracellular 
concentration of ATP, cause a decrease in RNA production and ultimately cell death.18 
The 8-chloroadenosine triphosphate also inhibits the polymerization of actin19 and the 
activity of topoisomerase II.20 It is currently being tested for activity against breast 
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cancer21-22 and is in a Phase I clinical trial for the treatment of chronic lymphocytic 
leukemia.23-24  
1.2  Click Chemistry 
"Click Chemistry" is a term first introduced by K. Barry Sharpless in 1998 and fully 
described in 2001 to describe reactions that generate substances by joining small building 
blocks together with heteroatom links (C-X-C). In his landmark review "Click 
Chemistry: Diverse Chemical Function from a Few Good Reactions,"25 Sharpless 
described a set of criteria that a reaction must meet to be considered a click reaction. 
Thus, a desirable click reaction should be high yielding, wide in scope, be stereospecific 
and create only inoffensive by-products that can be removed without chromatography. 
Simple reaction conditions, readily available starting materials and the use of a solvent 
that is benign or easily removed are other characteristics attributed to the click reaction. 
Several transformations have been identified to fit the concept of click chemistry, the 
most common examples being the cycloaddition of unsaturated species such as 1,3-
dipolar cycloaddition reactions and the Diels-Alder reactions.25 Nucleophilic substitution 
chemistry, specifically ring opening reactions of epoxides and other strained heterocyclic 
electrophiles, "non-aldol" type carbonyl chemistry and, oxidative addition to carbon-
carbon multiple bonds such as epoxidation and dihydroxylation are also considered to fit 
the concept of the ideal click reaction.  
1.2.1 Early Examples of Click Chemistry 
1.2.1.1 Huisgen Work 
The earliest 1,3-dipolar cycloadditions were described in the late 19th and early 
20th centuries; however, the bulk of the mechanistic investigation and synthetic 
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application was established by Rolf Huisgen in the 1960s. Thus, the 1,3-dipolar 
cycloaddition is the reaction of a dipolarophile and a 1,3-dipole to give a 5 membered 
heterocyclic ring reaction and is commonly referred to as the Huisgen cycloaddition.26 
Typically dipolarophiles are alkenes, alkynes and molecules that possess functional 
groups with heteroatoms such as carbonyls and nitriles. More recently, the Huisgen 
cycloaddition is often used to describe the 1,3-dipolar cycloaddition between an 
organic azide27-28 and an alkyne to generate 1,2,3-triazole, Scheme 1. The commonly 
employed Huisgen cycloaddition is slow and requires heating at upwards of 100 °C, often 
produceing mixtures of two regioisomers when an asymmetric alkyne is used.  
 
Scheme 1. Husigen 1,3-dipolar cycloaddition 
1.2.1.2 Sharpless Work 
In 2002 Morton Meldal,29 at the Carlsberg Laboratory in Denmark, and K. Barry 
Sharpless,30 at the Scripps Research Institute in California, independently developed a 
copper(I)-catalyzed Huisgen cycloaddition which they entitled the Copper-catalyzed 
Azide-Alkyne Cycloaddition (CuAAC), Scheme 2. The addition of the copper catalyst 
allowed the Huisgen reaction to proceed under mild and physiological conditions 
including room temperature. The CuAAC specifically allowed for the synthesis of the 
1,4-disubstituted regioisomers specifically.30 
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Scheme 2. Copper catalyzed azide alkyne cycloaddition 
Recently, click chemistry has found many applications in the broad areas of 
materials science,31 drug discovery,32 bioconjugation,33  proteomic profiling and potential 
identification of cellular targets.34 However, the cytotoxicity of copper is a major 
drawback of CuAAC and a limiting factor in the in vivo application of the copper 
catalyzed click reaction. The presence of copper and/or reducing agents such as sodium 
ascorbate have also been reported to cause DNA degradation35-37  or aggregation of 
biomolecules.38   
1.2.1.3 Bertozzi Work 
The strain promoted 1,3-dipolar [3+2] cycloaddition of azides and cyclooctynes 
(SPAAC) was later developed by Bertozzi and coworkers,39-44 as a modified Huisgen and 
Sharpless cycloaddition, Scheme 3. The SPAAC reactions occur readily under 
physiological conditions and in the absence of supplementary reagents such as copper 
and microwave heating. Furthermore, the SPAAC reaction is a bioorthogonal reaction 
because it can occur inside a living system without interfering with naturally occurring 
processes.39 The azide component of the reaction is bioorthogonal because it is small 
(similar size to a methyl group), metabolically stable, and does not naturally exist in cells. 
Although the alkyne is not quite as small as the azide, it is sill bioorthogonal enough for 
in vivo studies. The SPAAC reaction has been used for the selective modification of 
compounds or living cells40 including those in live zebrafish12 and mice.45 
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Scheme 3. Strain promoted 1,3-dipolar [3+2] cycloaddition 
The classic Sharpless copper-catalyzed click reaction is fast and effective for 
bioconjugation but unsuitable for live cells as a result of the toxicity of the copper ions 
required for the reaction. The need for copper catalysis was bypassed by strain promoted 
click reaction by exploiting the strain experienced by the alkyne (~18 kcal/mol) and 160° 
bond angle in the eight-membered ring deviating from the typical alkyne bond angle of 
180°, Figure 1.44  
 
Figure 1. Bond angle comparison in liner alkyne vs cyclooctyne 
The first cyclooctyne developed by the Bertozzi group, designated OCT, reacted 
with azides at room temperature but lacked water solubility,39 Figure 2. The aryl-less 
octyne, ALO, had improved water solubility but was still sluggish when reacting with 
azide partners.  The monofluorinated cyclooctyne, MOFO, and difluorinated 
cyclooctyne, DIFO, were created to increase reaction rate though electronic modulation 
by the addition of an electron-withdrawing fluorine. The dibenzylcyclooctyne, DIBO, 
was developed by fusing two aryl rings onto a simple cyclooctyne, resulting in high ring 
strain and a decrease in distortion energy.44 The biarylazacyclooctynone, known as 
BARAC, is an analogue of DIBO with an amide bond in the ring which adds an sp2 
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center and increases reaction rate by ring distortion. Adjustments on the structure of 
BARAC yielded DIBAC by adding distal ring strain which reduced the steric bulk 
around the alkyne and further increased reactivity of the alkyne. The 
dimethoxyazacyclooctyne, DIMAC, was developed in response to DIFO being 
extremely reactive in labeling live cells but performing poorly in animal models. The two 
methoxy groups α and β to the alkyne increased DIMAC's water solubility, polarity and 
its pharmokinetics.46  
 
Figure 2. Representative Cyclooctynes39-50 
The most popular application of the SPAAC reaction is in imaging of live cells or 
animals using an azide tagged biomolecule and cyclooctyne with an imaging agent.48 
Copper-free click chemistry is also being explored for the synthesis of Positron Emission 
Tomography (PET) imaging agents. A challenge for the click-PET probes is rapid 
synthesis of the cyclooctyne to minimize the isotopic decay of the radionuclides (18F or 
64Cu).51-53  
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1.2.2 Click Chemistry with Nucleosides and Nucleotides 
Click chemistry was developed to provide a simple method for joining organic 
building blocks and has been applied extensively for introduction of substituents onto 
nucleosides, nucleotides, nucleic acids and DNA. Nucleosides and oligonucleotides with 
alkyne modified heterocyclic bases have been conjugated with azide modified fluorescent 
dyes, sugars and peptides for imaging and drug discovery.33, 54-56  
1.2.2.1 Azide Modified Sugars 
The discovery of therapeutically applicable azido sugar modified nucleosides 
such as Zidovudine, AZT, Figure 3, provided the foundation for the discovery and 
application of other azido modified sugar derivatives of nucleosides.  
 
Figure 3. Example of an azido sugar modified nucleosides, Zidovudine (AZT) 
1.2.2.1.1 Copper Catalyzed Click Chemistry 
The Cu(I) catalyzed click reaction has been utilized towards the functionalization 
of sugar moieties on nucleosides. In 2005, Zhou et al.57 reported the synthesis of various 
analogues of the antiviral AZT with hydroxyl 1, amino 2 and carboxylic 3-5 
modifications, Figure 4; however these compounds, were found to be inactive against 
several viruses including HIV, herpes simplex, and cowpox. Inactivity of 3'-azido 
modified AZT can at least be party attributed to a failure to be phosphorylated by cellular 
or viral kinases. Later, AZT was also conjugated with a series of propargyl β-D-
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glycosides via a copper catalyzed click reaction to give 1,2,3-triazole linked 
oligosaccharides 6-9,58 providing a new avenue for attaching carbohydrate residues to 
pharmaceutical compounds, Figure 4.  
 
Figure 4. 3'-Triazolo modified thymidine analogues57-58 
The 5'-triazolo modified thymidine analogues 11-14 were synthesized by Byun et 
al. from 5'-azide 10 using Sharpless "style" click chemistry, Scheme 4.59 In vitro growth 
inhibition studies of the analogues on B. anthrasis Sterne revealed that only compound 
12, with a para-fluoro substituent on the phenyl ring, was active (IC50 of 113 µM).  
 
Scheme 4. 5'-Triazolo Modified Thymidine59 
Double headed nucleosides are nucleosides that contain two nucleobases. They 
have been used as building blocks of unnatural nucleic acids.60-65 Dimer 16 was an 
attempt by Danel et al.65 to synthesize an asymmetric, double headed nucleoside drug via 
CuAAC reaction, Scheme 5. Thus, AZT was conjugated with the thymine analogue 15,66 
a known potent inhibitor of HIV-1, to afford triazole 16. The di-thymine analogue 16 
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demonstrated activity against wild type HIV-1 and mutant strains. However, derivative 
16 showed low activity against the drug resistant Y181C mutated stain; therefore, it is 
unlikely that the nucleoside portion of 16 functions as a reverse transcriptase inhibitor.65  
 
Scheme 5. Synthesis of double headed thymidine65 
Recently, locked nucleic acids (LNAs) have received attention because of their 
promising therapeutic antisense properties.67-69 Enderlin and Nielsen70 used CuAAC with 
microwave heating to synthesize the double-headed nucleoside 18 with a triazole linking 
an additional thymine to the 6'-position of the LNA-nucleoside monomer, Scheme 6. 
When the phosphoramidite of triazole 18 was incorporated into an oligonucleotide 19 a 
large increase in thermal stability was seen and the bulky substituent was well 
accommodated in the minor groove;71 thus, double headed nucleosides can be an 
important tool in the construction of artificial oligonucleotides.   
 
Scheme 6. Synthesis of locked thymdine via CuAAC70 
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Cytidine and adenosine analogues with 5'-triazole moieties were prepared by 
conversion of a 5'-phosphate ester intermediate followed by an azide substitution reaction 
and click reaction in the presence of copper sulfate and sodium ascorbate. Resulting 
compounds 20-26, Figure 5, were evaluated against α-2,3-sialyl-transferase. Interestingly, 
cytidine analogue 23 with the phenyl substituent was the most active compound with an 
IC50 of 37.5 µM, suggesting that a hydrophobic functionality and a cytosine ring are 
necessary for optimal binding and inhibition.72 Novel acyltriazole adenosine 27 was 
synthesized via a click cycloaddition between protected 5'-azido-5'-deoxyadenosine and a 
carboxyalkyne. It was examined as an inhibitor of Mycobacterium tuberculosis but 
showed no inhibition of growth up to 100 µM. Molecular modeling of 27 showed the 
hydrogen bonds involving the phosphate of the natural substrate are lost when the triazole 
replaces the phosphate. Furthermore, the planar geometry of the triazole was a poor fit for 
the binding site, requiring out of plane bending of the ring substituents.73   
 
Figure 5. 5'-Triazolo modified cytidine and adenosine analogues72-73 
The Grøtli group employed a copper(I)-catalyzed [3+2] cycloaddition reaction 
between 2'-azido-2'-deoxyadenosine and various alkynes using catalytic amounts of 
sodium ascorbate and copper sulfate overnight at ambient temperature to give analogues 
28-36, Figure 6.74 These compounds are considered non-hydrolyzable isoteres of 2'-
aminoacyladenoisne that are a crucial component in the tRNA synthetases enzymatic 
cascade and currently are of use in x-ray crystallographic studies for the elucidation of 
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the editing mechanism of various tRNA synthetases.75  
 
Figure 6. 2'-Triazolo Modified Adenosine Analogues74 
Kosiova et al.76 prepared novel coumarin-nucleoside conjugates via a Cu(I) 
catalyzed click reaction of an alkyne modified coumarin and a 3'- or 5'- azido modified 
thymidine, Figure 7. The resulting triazoles 37 and 38 exhibited promising fluorescent 
properties. The fluorescent intensity of the newly synthesized conjugates depended on the 
position of the of the coumarin modification. The approach for using coumarin as a 
fluorescence reporter is also currently being used for the preparation of fluorescent 
bioconjugates including fluorescent carbohydrates.77 
 
Figure 7. Thymidine-coumarin conjugates76 
Novel oligonucleotides 40 and 41 containing triazole residues with nucleobase 
tethers were synthesized via CuAAC of N-9 propargylpurines or N-1 
propargylpyrimidines with the tolouyl protected 1-azido-2'-deoxyribofuranose 39, 
Scheme 7. Melting experiments of the resulting oligodeoxynucleotides (ODN's) 
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demonstrated that triazole nucleosides destabilize DNA duplexes. The destabilization is 
the result of the inability of tethered nucleosides to form base pairs with opposite bases 
because of the structural variations caused by the auxiliary triazole ring.78 
 
Scheme 7. Synthesis of DNA containing triazole-bridged nucleobases78 
1.2.2.1.2 Strain Promoted Click Chemistry 
The strain promoted click reaction (SPAAC) has been much less extensively 
studied on azido modified sugars. A SPAAC reaction has been reported at the 2'-azide 
position of all four possible bases (A, C, G, U) which were incorporated at the 3' terminus 
on a strand of RNA 42, Scheme 8. The ligase mediated site specific incorporation of a 
single modified nucleotide of choice (A, C, G, U) containing an azide made this method 
unique. Furthermore, the azide 42 was reacted with a fluorophore cycloalkyne to give site 
specific fluorescent labeling of the de novo synthesized RNA 43.79  
 
Scheme 8. Site specific SPAAC on the 3' terminus of RNA79  
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1.2.2.2 Alkyne Modified Sugars 
As previously described modification of the sugar moiety is usually preferred to 
modification on the base because it has, in general, a less negative impact on the resultant 
oligonucleotide and can sometimes improve the oligonucleotide's thermodynamics. 
1.2.2.2.1 Copper Catalyzed Click Chemistry 
The appendage or substitution of an azide is one of the most preferred 
modifications on a sugar; therefore, the alkyne modification on the sugar is more difficult 
to accomplish and has thus been explored less often. Attachment of a propargyl group at 
the 2'-hydroxyl group of the ribose sugar on a stand of DNA does not affect duplex 
stability making the 2'-position ideal for label attachment. This tagging strategy has been 
employed by Berndl et al.80 for the post-modification of oligonucleotides, Figure 8. The 
2'-propargyl modified uridine was conjugated via a copper catalyzed click reaction to 
blue phenoxazinium azide yielding blue fluorescent product 44 or red coumarin azide 
yielding triazole 45. Interestingly, the 2'-dye modified uridines 44 and 45 still base pair 
with adenine and do not exhibit reduced thermal stability compared with unmodified 
duplexes. A Stokes shift of ~100 nm was also observed, validating this approach as a 
convenient fluorescent label for nucleic acids in assays or cell biology.  
 
Figure 8. Fluorescent dye labeling of uridine in ODNs using the CuAAC reaction80 
Solid phase synthesis (SPOS) using phosphoramidites is the preferred method for 
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the synthesis of oligonucleotides.81 Triazole analogues modified with either 5'-linoleyl 47 
or N-Acetylgalactosamine (GalNAc) 48 moieties, were prepared by Yamada et al.82 via a 
CuAAC reaction in which the Cu(I) catalyst was made in situ from [Cu(CH3CN)4]PF6 
and elemental copper, Scheme 9. These analogues were later phosphorylated and 
incorporated into oligonucleotides, yielding small interfering RNA (siRNA) analogues 
which effectively silenced expression of the luciferase gene in HeLa cells.82  
 
Scheme 9. Synthesis of 5'-linoleyl and N-acetylgalactosaminyl uridine click monomers82 
Kawagoe et al.83 prepared thymidine 49 bearing a propargylic group at the C6' via 
a selective bromination followed by a substitution. The alkyne 49 was then reacted with 
6-azido-6-deoxycellulose 50 in the presence of CuBr2 to give the click adduct 51, Scheme 
10. Interestingly, 51 was observed to form nanocomposites and function as "wrapping 
papers" to disperse single-walled carbon nanotubes in water.  
 
Scheme 10. Synthesis of 2'-deoxythymidine modules onto cellulose main chain83 
Incorporation of a triazole ring into ODNs has been used to confer enhanced 
resistance to chemical and enzymatic degradation.84-85 Therefore, because of their 
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potential antitumor and antiviral properties, functionalized ODN's have recently received 
much attention. Varizhuk et al.86 synthesized a dinucleoside building block 54 with 
internucleotide linkage using click chemistry, Scheme 11. A two-phase solvent system 
(CH2Cl2/H2O) was used to increase the click reaction rate as the starting materials alkyne 
52 and azido 53 had poor solubility in the typical click reaction solvents.86 Melting 
temperature studies revealed that these short triazole linkages distort the double helix and 
cause destabilization of the duplex.  
 
Scheme 11. Fragment of modified ODN with triazole linkage86 
The RNA oligonucleotides containing triazole linkages between uridine and adenosine 
nucleosides have been reported.87-90 Mutisya et al.87 prepared the key triazole intermediate 57 
using a click reaction between 2'-O-alkynylated uridine 55 and N-benzoyl protected azido 
adenosine derivative 56, Scheme 12. As shown by UV melting and circular dichroism (CD) of the 
modified oligonucleotide once incorporated into RNA, 57 strongly destabilized the RNA duplex. 
Nuclear magnetic resonance (NMR) studies also conducted suggested that in spite of the relative 
flexibility around the modified linkage, all base pairs were formed. 
17 
 
 
Scheme 12. Fragment of modified ONs with a six-bond triazole linkage87 
The Pujari group conducted some interesting studies involving antiparallel strands 
of DNA ligated using a "bis-click" protocol, where in 2'-O-propargylated ribonucleosides 
were reacted in a click reaction with a bis-azide in the presence of a copper catalyst 
yielding 3'-5'-oligonucleotide 58, Figure 9.90 The modification displayed only a minor 
effect on duplex stability and allowed the DNA duplex to remain intact. The "bis-click" 
protocol was similarly utilized with 3'-O-propargylated ribonucleosides resulting in an 
unusual 2' and 5' phosphodiester linkage and increased destabilization.89 This new 
methodology is unique in that it can be introduced at any position (terminal or internal) in 
the oligonucleotide and theoretically be applicable to any nucleoside substrate bearing a 
propargylic group on the sugar moiety. Recently, Pujari and Seela introduced internal 
sugar cross-links into oligonucleotides with parallel chain orientation.90 They found that 
the cross-links stabilize anti-parallel and parallel duplexes significantly. Furthermore, the 
increase in Tm is similar in both cases, indicating that he cross-links are well 
accommodated leading to strong stabilization, which is unexpected as the anti-parallel 
and parallel strands of DNA have different geometries.  
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Figure 9. Sugar cross linked DNA90 
Recently, the synthetic advantage of microwave assisted click chemistry has also 
been applied to solid phase bound oligonucleotides.82 A variety of solid supported alkyne 
oligonucleotide scaffolds (e.g., 59) were shown to conjugate to virtually any azido-
functionalized ligand.82 The microwave click reaction was versatile in that it readily 
occurred at a desired site within the oligonucleotide sequence and at any selected position 
on the ribosugar (2', 3' or 5' positions) to yield 5'-triazole 60, Scheme 13.  The siRNA 
conjugate 60 was evaluated for in vitro RNAi activity using a HeLa cell line transformed 
with the firefly and renilla luciferase gene and demonstrated the capacity to effectively 
silence the expression of the luciferase gene. Although, this approach was demonstrated 
on uridine derivatives, it is applicable to other propargylated compounds.91-93  
 
Scheme 13. Click reaction of an azide with alkyne-oligonucleotide scaffold82 
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El-Sagheer and Brown utilized a copper catalyzed click reaction of 3'-azide 61 
and 5'-propargylamido 62 to prepare DNA strand 63, with unnatural triazole linkage, as a 
PCR template.94 Amplification of template 63 proceeded efficiently with a variety of 
polymerases to give amplicon 64, Scheme 14. Sequencing of the DNA amplicon revealed 
the presence of a single thymidine at the ligation site, making this the first example of 
highly efficient nonenzymatic DNA strand ligation combined with reproducible 
amplification. The ability of thermostable polymerases to read through such an unnatural 
backbone opens up intriguing possibilities in biology and nanotechnology. 
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Scheme 14. Click Ligation of Alkyne and Azide Oligonucleotides Produces a PCR Template94 
1.2.2.2.2 Strain Promoted Click Chemistry 
Copper free click chemistry is a mild and fast method for the selective 
conjugation and modification of ONs. The site-specific introduction of the requisite large 
(and typically hydrophobic) cyclooctynes has proved challenging. Jawalekar et al. 
reported a method for incorporating of bicyclo[6.1.0]nonyne (BCN) into synthetic ODNs 
using standard solid phase phosphoramidite chemistry, Scheme 15.95 Thus, 2'-amino 
modified ODN 65 was coupled with azidohexanoic acid or a BCN derivative and later 
cleaved from solid support to give either azide derivative 66 or BCN-derivative 67, 
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respectively. Overnight stirring of azide 66 and cyclooctyne 67 gave the corresponding 
triazole linked oligo 68; confirmed by HPLC and MALDI-TOF. This cross-linking 
approach was unique in that it demonstrated a straightforward and high-yielding 
conjugation of ODNs at any adenosine in the ribose backbone of RNA.  
 
Scheme 15. RNA dimerization via SPAAC95 
1.2.2.3 Azide Modified Bases 
Azide modified sugars such as AZT have also been studied in click chemistry, 
with typical reaction conditions including the addition of Cu(I) and microwave assisted 
heating.96-99 However, the application of the nucleosides bearing an azido group in 
heterocyclic bases in the click chemistry with alkyne partners has received much less 
attention thus far. A limiting factor in the development of base modified azido 
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nucleosides and oligonucleotides is their lack of compatibility with the solid-phase 
synthesis of DNA fragments which required trivalent phosphorous-based precursors. 
1.2.2.3.1 Copper Catalyzed Click Chemistry 
Owing to their relatively high stability, aryl azides have found many biological 
and industrial uses.100 However, aryl azides have also been found to be relatively 
unreactive in click reactions and usually require extensive heating for a reaction to 
occur.101-103 The Hudson group demonstrated the unreactivity of 8-azidoadenosine 69 
with terminal alkyne bearing cyclen Eu3+ complex 70 even after prolonged reaction times 
(120 h), addition of a large excess of CuSO4·5H2O and sodium ascorbate and refluxing in 
DMF, Scheme 16.101  
 
Scheme 16. Click Reaction between azido modified adenosine and cyclen Eu3+ complex101 
Gunji and Vasella demonstrated the "inconsistent" reactivity of base modified 
nucleosides in CuAAC reactions. Reaction of protected 8-azidoadenosine 71 with 
(trimethylsilyl)acetylene at 80 °C for 20 h afforded triazole product 72 in modest yields; 
however, azide 71 was unreactive when reacted with phenyl acetylene and did not yield 
triazole 73, Scheme 17.103 
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Scheme 17. Synthesis of protected 8-triazole adenosines103 
 Similar to the results previously mentioned by Gunji,103 Schaeffer104 prepared the  
protected 2-azidoadenosine 74 that was only moderately reactive in copper catalyzed 
click reactions and which also required excess of alkyne and a prolonged reaction times, 
Scheme 18.105 The click analogues 75 – 81 constitute a novel class of highly potent and 
selective Gi-coupled A3 adenosine receptor (A3AR) partial agonists and antagonists with 
"potential" to be used as pharmacological agents. 
 
Scheme 18. Synthesis of 2-Triazole-1-yl Analogues of N6-Methyladenosine105 
A library of 2-triazole substituted analogues of 5′-O-[N-
(Salicyl)sulfamoyl]adenosine (e.g., 83 and 84) were synthesized by Gupte via a Cu(I)-
catalyzed click reaction of azide 82 with a panel of 30 alkynes, Scheme 19.106 The 30 
alkynes were selected systematically to explore the van der Waal and electrostatic 
interactions provided by the subsequent 1,4-substitued triazoles, Scheme 17. Evaluation 
of these analogues for effects on the aryl acid adenylating enzyme (AAAE) known as 
MbtA and activity against whole-cell M. tuberculosis under iron-deficient and iron-
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replete conditions, demonstrated remarkably, all compounds having potent AAAE 
inhibition. Furthermore, on the basis of potency, selectivity, lack of cytotoxicity and 
decreased hydrophobicity, phenyltriazole 84 proved to be the best candidate of the 
analogues tested and merits further clinical evaluation against M. tuberculosis. 
 
Scheme 19. Synthesis of 2 triazole analogues of 5′-O-[N-(Salicyl)sulfamoyl]adenosine106 
Lakshman prepared C2-triazolylinosine derivatives using CuAAC, Scheme 20, 
and the compounds were evaluated for antiviral activity against a broad spectrum of 
DNA and RNA viruses. None of the OTBDMS protected analogues proved to be active 
against most of the tested viral strains at sub-cytotoxic concentrations. It is worthy to note 
that moderate inhibitory activities were observed for the phenyltriazole 86 and 
butyltriazole 87 against vesicular stomatitis virus and cytomegalovirus, respectively.107   
 
Scheme 20. Synthesis of C-2 Triazolinosine Derivatives107 
Azido modified pyrimidine nucleosides have also been shown to undergo the 
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robust labeling of cellular DNA forming triazole 92, Scheme 22.110 
 
Scheme 22. Click metabolic labeling of DNA110 
Jin et al.114-115 saw a potential application for the CuAAC reaction by conjugating 
various carbohydrates with bicyclic furo[2,3-d]pyrimidine thymidine analogues active 
against varicella-zoster virus (VZV), Scheme 23.116 The concept was varying the 
carbohydrate moiety would offer improved solubility and molecular recognition of their 
active parent drugs. Thus, the azido analogue 90 was reacted with various propargylic 
carbohydrate derivatives in the presence of CuSO4 and sodium ascorbate to give 
corresponding triazole sugars derivative of type 94. The biological testing of the 
aforementioned deprotected substrates of type 94 has yet to be reported.117 
 
Scheme 23. Synthesis of Bicyclic Pyrimidine Nucleosides116 
1.2.2.3.2 Strain Promoted Click Chemistry 
One of the most important secondary messengers in the human body is 3′,5′-
Cyclic adenosine monophosphate (cAMP);118-120 however, its direct detection has always 
been troublesome.121-123 The previously developed detection sensors depend on protein 
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expression to measure cAMP which is unavoidably insensitive and do not directly detect 
cAMP.121-123 The 8-Azidoadenosine 3′,5′-cyclic monophosphate (8-azido cAMP) 95, a 
direct analogue of the naturally occurring cAMP, was directly detected in living cells by 
applying SPAAC.124 By incorporating a DIFO41-42, 45 probe via a click reaction, it was 
possible to directly detect the fluorescent cAMP derivative 96 in living cells without the 
usual fixing and washing steps, Scheme 24. This approach may allow be a detection 
method for specific intracellular sites of cAMP derivatives and enable the real time 
measurement of cAMP fluctuations.124 
 
Scheme 24. Strain promoted click chemistry of 8-azido-cAMP124 
As previously discussed, 5-(azidomethyl)-2'-deoxyuridine 91 was synthesized by 
the Luedtke group in an effort to overcome the instability observed with 5-azidouridine 
90 and to evaluate the potential metabolic incorporation and detection of azide groups in 
cellular DNA.110 To evaluate the reactivity of azide 91 in SPAAC, a fluorescent alkyne 
derivative was added and strain promoted click reaction ensued with significant labeling 
of cellular DNA forming triazole 97 and bright fluorescence, Scheme 25.110 Covalent 
attachment of a bulky substituent to DNA, resulted in a loss of cellular respiration; 
measured 4h after SPAAC labeling. This tagging method, is useful for the detection of 
azide-modified DNA near the end of live-cell experiment, especially in cases where 
fixation and/or copper salts lead to degradation of the specimen.36  
27 
 
 
Scheme 25. SPAAC of 5-azidomethyl-2'-deoxyuridine110 
1.2.2.4 Alkyne Modified Bases 
The introduction of an alkyne onto nucleoside bases can easily be accomplished 
using a palladium catalyzed Sonogashira reaction.125  Thereby, the synthesis and use of 
alkyne modified nucleosides is popular with click reactions.  
1.2.2.4.1 Copper Catalyzed Click Chemistry 
A series of 8-triazole modified adenosine derivatives was prepared by Dyrager et 
al.126 from 8-acetylene modified adenosine 98 using a Sonogashira coupling and CuAAC, 
Scheme 26. The modified nucleosides 99 - 107 showed high absorptivities attributed to a 
single electronic transition; the isopentyl derivative 102 was also noted as having high 
fluorescence quantum yields.126 Further studies of the pentyl analogue 103 showed that 
DNA duplexes are only slightly destabilized by steric clashes of the substituent triazole 
ring and pentyl chain with the phosphate backbone and sugar moieties. Steric clash would 
account for a considerable energy cost if the base is to be accommodated in the duplex in 
its anti-conformation to cause minimal structural perturbations to normal B-DNA.127 
Interestingly, it was found that 103 forms equally stable base pairs not only with 
thymidine but also normal adenine residues.127 The excellent photophysical properties of 
the target compounds 99 - 107 along with an intact hydrogen-bonding pattern make these 
analogues promising fluorescent probes of nucleic acids.   
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Scheme 26. Synthesis of Fluorescent 8-Triazoyl Adenosine Derivative126 
Using the same method previously described by Dyrager126 and Dierckx,127 
O'Mahony and coworkers128 employed a Huisgen intramolecular [3+2]-cycloaddition 
between a 2'-modified azide and a disubstituted alkyne 108 by microwave heating at 150 
°C for 15 min to afford several novel adenosine containing cyclonucleosides (e.g., 109), 
with fluorescence in the visible range, Scheme 27. Triazole modified adenosine 109 is 
expected to act as a biological probe because of its inherent fluorescent properties; 
thereby, circumventing the need for any additional and typically bulky fluorescent 
labels.129 
 
Scheme 27. Cyclonucleosides synthesized using click chemistry128 
Cosyn et al.105 prepared a series of 1,2,3-triazol-4-yl adenosine analogues 111 – 
113 employing copper catalyzed click chemistry on C-2 acetylene adenosine, Scheme 28. 
Binding affinities of the adenosine triazole derivatives 111 – 113 were measured in CHO 
(Chinese hamster ovary) cells at the human A1, A2A, and A3AR (G-protein-coupled 
adenosine) receptors. It was found that analogues 111 - 113 constitute a new class of 
highly potent and selective A3AR antagonists, partial agonists and agonists.  
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Scheme 28. Synthesis of 2-Triazole-4-yl Analogues of N6-Methyladenosine105 
The Nielsen group synthesized 5-modifed 2'-deoxyuridine nucleosides using 
copper catalyzed click chemistry109, 130 and later incorporated into oligonucleotides using 
a solid phase oligonucleotide synthesis to give analogues 114 and 115, Figure 11.78, 98 
The meta-aminomethyl substituent on the phenyl ring of 115 was found to thermally 
stabilize a 9-mer DNA:RNA duplex, presumably through the partial neutralization of the 
negatively charged phosphate backbone. Additionally, a high thermal stability was 
observed in ODN 115 as a consequence of the stacking interactions of the aminomethyl 
moiety in the major groove. 
 
Figure 11. Structure of 5-fuctionalized 2'-deoxyuridine oligonucleotides78,98 
Gierlich et al.112 developed a CuAAC protocol for the multiple postsynthetic 
labeling of alkyne modified DNA. They prepared a series of alkyne modified ODNs of 
type 117 from 5-ethynyluridine 116 and investigated the click reaction using various 
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azide labels, Scheme 29. Complete conversion to the click product 118 was seen for 
ODNs that had up to six consecutive 5-acetylene uridine residues. This method is also 
applicable to long DNA strands obtained by PCR and is currently being investigated for 
the detection of single nucleotide polymorphism in the human p53 suppressor gene131 and 
for the synthesis of backbone branched DNA.132-134 In another study by Jao and Salic,135 
5-ethylnyluridine labeled cellular RNA 110 was detected quickly and with high 
sensitivity using CuAAC with a fluorescent azide partner. Using fluorescent microscopy 
imaging, it was found that transcription rates vary greatly among the different tissue 
samples and cells within organs.135  
 
Scheme 29. Postsynthetic Functionalization of Alkyne Modified DNA112 
The Fujimoto group incorporated the 5-ethynylvinyl-2'-deoxyuridine 
phosphoramidite into an ODN using standard solid phase synthesis which gave the 
alkyne modified ODN 119. Fujimoto et al.136 carried out a CuAAC on alkyne 119 using 
several different azides which gave photoreactive triazole 120, Scheme 30. The triazole 
modified ODNs of type 120 were subjected to photoligation with ODNs containing 3'-
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cytosine bases; efficiency of ODN ligation was confirmed by HPLC analysis. The 5-
ethynylvinyl-2'-deoxyuridine photosensitive ODN probe was also useful for the 
construction of a single nucleotide polymorphism (SNP) probe.136-139  
 
Scheme 30. DNA Photoligation via CuAAC136 
The Seela group has used CuAAC to introduce two fluorescent labels into a single 
thymidine monomer, Scheme 31.134 The 5-tripropargylamine-2'-deoxyuridine 121 via a 
Sonogashira coupling, then converted it to a phosphoramidite monomer and incorporated 
it into an ODN. The resulting tripropargyl modified nucleoside 121 was clicked to non-
fluorescent 3-azido-7-hydroxycoumarin to give ditriazole derivative 122. The bis-labeled 
ODN 122 was less fluorescent than ODNs labeled with a single coumarin triazole 
because of self-quenching between the fluorophores. However, the tripropargyl analogue 
121 was found to slightly stabilize DNA duplexes because of the “clickable” moieties 
protruding into the major groove of duplex DNA which do not disturb the base stacking.  
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Scheme 31. Synthesis of DNA with branched internal side chains134 
DNA is an ideal material for the preparation of nano- and microscale assemblies 
which can be used in nanoelectric devices. Burley et al.111 found that DNA strands of 
interest can be selectively metallized via the incorporation of 5-acetylene containing 
nucleotide triphosphates. Thus, the Burley group used a click reaction of acetylene 
derivative 123 with an azide bearing a terminal aldehyde moiety, as a chemical reporter, 
to give the click adduct 124, Scheme 32. Further treatment of the aldehyde-labeled DNA 
124 with the Tollens reagent, [Ag(NH3)2]+, results in the selective metallization of 
modified strands of DNA. Experiments to determine whether metallized DNA strands 
constructed using the aforementioned method conduct electricity are currently 
underway.111, 140-141  
 
Scheme 32. Directed DNA metallization via CuAAC111 
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The Zhang group developed the novel 5-ethynyl-2′-deoxycytidine142 (EdC) 
method for the detection of DNA synthesis in vitro and in vivo with a comparable 
sensitivity level to the commonly emplyed and highly cytotoxic143 5-ethynyl-2′-
deoxyuridine.144-145 The EdC that was added to culture medium of 
adenocarcinomic human alveolar basal epithelial cells (A549) were incorporated by 
cellular polymerases into newly synthesized DNA to give alkynylated DNA strands 126. 
These modified DNA strands were then subjected to CuAAC in the presence of a Cy3-
azide and CuSO4 which afforded fluorescent the derivative 127 and was visualized with 
fluorescent microscopy, Scheme 33. Incorporation of EdC can be used for the long term 
detection and visualization of DNA synthesis because of its non-cytotoxic nature.  
 
Scheme 33. DNA labeling with fluorescent azide142 
1.2.2.4.2 Strain Promoted Click Chemistry 
Ren et al.146 labeled the 5-amino group of key intermediate 2'-dUTP 128 with 
either BCN or DIBO to give 129 or 131, respectively, which were then incorporated into 
DNA by linear extension using two different templates and a variety of DNA 
polymerases, Scheme 34. Labeling of the modified extension products (129 or 131) with 
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Cy3-hexylazide via the SPAAC reaction gave either ODN, 130 or 132, both of which 
demonstrated the efficient labeling of these cyclooctyne modified ODNs, Scheme 34. 
The acceptance of the cyclooctyne modified triphosphates (129 and 131) as substrates for 
DNA polymerase substrates in PCR is encouraging for future in vitro and in vivo 
biological and medicinal applications.  
 
Scheme 34. Labeling of amino-propargyl-dUTP with BCN and DIBO146 
Rotaxane is a multicomponent molecule consisting of a dumbbell shaped 
molecule which is threaded through a macrocycle. Recently, the rotaxane architecture has 
been extended to nucleic acids for DNA nanotechnology,147-152 topological labels153-156 
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and the stabilization of triplex formation.157-159 Onizuka et al.160 designed a novel method 
for templated pseudorotaxane formation that targets nucleic acids using a pair of reactive 
ODNs, Scheme 35. Thus, the two components Onizuka envisioned were ODN 133 with 
DBCO in the internal position and a phosphorothioate group at the 3' end and ODN 134 
which contains an azide moiety at the internal position and a chloroacetyl group at the 5' 
end. When reacted together an SN2 type chemical ligation was observed between the 
phosphorothioate group (3' end) and chloroacetyl group (5' end). The SPAAC reaction 
also proceeded between the internal DBCO and azide groups when the two ODNs 
hybridized with a DNA at the proper position to give pseudorotaxane 135. Once formed, 
pseudorotaxane disassociates from its complimentary DNA strand to give ODN 136 
which is able to reversibly slip off of the DNA template to give free circular ODN 137. 
This new methodology for the formation of a pseudorotaxane with any single stranded 
nucleic acid using only a pair of ODNs, a SPAAC and a substitution reaction paves the 
way for a variety of applications including new DNA nanotechnologies and antisense 
ODNs.160 
 
Scheme 35. Schematic representation of pseudorotaxane formation via SPAAC160 
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1.2.2.5 Miscellaneous Strain Promoted Click Chemistry 
Several groups including Bertozzi and coworkers,39-40 Boons161 and van Delft95, 
162-163 have worked towards the development of a catalyst free click reaction (SPAAC). 
The SPAAC reaction has been applied to the selective modification of compounds or 
living cells40 including live zebrafish12 and mice.45 However, one area that remains less 
explored is the bioconjugation of DNA through the phosphate backbone.  
The Taton group described the solid-phase synthesis and characterization of 5'-
DIBO modified oligonucleotides 139, prepared using a new DIBO phosphoramidite 138, 
Scheme 36.164 As expected, the DIBO modified ODN 139 reacted quantitatively with 
organic azides to give click adducts 140 and 141. Cyclooctyne modified ODN 139 was 
also used as a PCR primer for the amplification of a 500 base-pair sequence from 
bacteriophage λ DNA.164 Incubation of the crude PCR mixture with fluorescent dye, 
Texas Red azide, and further agarose gel electrophoresis of the PCR product 
demonstrated that the amplification with primer 139 had been successful and that the 
DIBO group remained reactive as indicated by the Texas Red labeled product 140. A 
similar labeling method is currently being used by van Delft for the conjugation of RNA 
to a phosphoramidite modified DIBO.165 
 
Scheme 36. SPAAC for terminal labeling of DNA164 
Kim and colleagues developed a method for labeling zinc finger proteins (ZFP) 
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using SPAAC, Scheme 37.166 An azide modified ZFP 143 was reacted with DIBO 
conjugated dye 142 resulting in fluorescently labeled ZFP 144, Scheme 37. Typically the 
DNA binding activity of ZFPs labeled by copper catalyzed click chemistry is completely 
eliminated.167 However, when ZFPs were labeled using SPAAC to give 145, the DNA 
binding activity was retained under native conditions. The labeling strategy using DBCO 
and an azide modified protein can also be applied for the labeling of other 
metalloproteins containing copper or iron cofactors.168 
 
Scheme 37. SPAAC for the conjugation of DBCO-dyes to Zinc finger proteins166 
Small interfering RNAs have been shown to be powerful tools for silencing 
expression of specific genes and have the potential to become a class of powerful 
therapeutics;169 however, their efficient distribution and intracellular delivery in vivo 
remains challenging.170 Jayaprakash et al.171 designed a conjugation strategy between 
RNA ONs and several ligands that should improve cellular delivery of siRNAs. Thus, 
DIBO modified ON 146 was reacted in a SPAAC reaction with several azides to 
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quantitatively give click adducts of type 147, Scheme 38. This procedure served as a 
foundation for the development of new methods for the functionalization of RNA by 
click chemistry. Variations of this RNA tagging methodology were recently reported by 
the Heaney group for solid phase post-synthetic RNA conjugation172 and by the 
Rentmeister group for the bioorthogonal site-specific labeling of the 5'-cap structure of 
eukaryotic mRNAs.173 
 
Scheme 38. RNA conjugation by SPAAC171 
The El-Sagheer group designed a SPAAC reaction for the ligation of templated 
DNA, Scheme 39.174 The controlled ligation of templated DNA occurs only in the 
presence of a complimentary DNA template, ensuring that only the desired DNA duplex 
is formed; the presence of a single base pair mismatch was shown in being sufficient to 
inhibit this reaction from occurring. Thus, triazole 149 was formed as soon as the two 
new DNA strands of 148 became correctly templated with the existing DNA primer.  
Interestingly, the addition of Cu(I) completely inhibited this SPAAC reaction, probably 
as a result of the complexation of the cyclooctyne with the copper ions. The labeling 
protocol has possible applications in biology, genomics175 and nanotechnology;176-177 and 
is currently being used to build topological polymers178 and very long oligonucleotides.179 
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Scheme 39. SPAAC DNA ligation between azide and cyclooctyne labeled ODNs174 
1.3 Synthesis and Biological Applications of Fluorescent Nucleosides 
Naturally occurring nucleic acid components are usually non-fluorescent; 
therefore, fluorescence has typically been conferred on nucleosides by several methods 
including extending π conjugation of the heterocyclic base180-181 or by conjugation with 
known fluorophores.182-183  When carefully implemented, fluorescent nucleosides have 
been used to determine fundamental biochemical transformations and have become 
instrumental in modern nucleic acids biophysics.184-186 
1.3.1 Naturally Occurring Fluorescent Base Analogues 
Naturally occurring modified nucleosides 150 – 153 are all slightly fluorescent 
and have been used by Bokacheva and coworkers187-189 as reporter probes for tRNA, 
Figure 12. The use of analogues 150 - 152 in observing the structure and dynamics of 
tRNA has not been widespread because of their weak emissive properties.190-191 The 
Wyosine derivative 153, in contrast, emits strongly and has been used to study the tertiary 
structure of tRNA.192   
 
Figure 12. Naturally occurring fluorescent nucleosides. R = ribose 
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1.3.2 Synthetic Modifications to the Base 
Synthetic modifications to the purine and pyrimidine bases have been widely used 
to confer fluorescent properties to nucleosides and oligonucleotides. 
1.3.2.1  Base Replacements 
Purine and pyrimidine bases have been replaced with hydrocarbon and 
heterocyclic rings resulting in modified nucleosides with fluorescent properties Figure 
13. Fluorescent analogues 154 and 155 were synthesized by Strassler et al., through a 
Grignard reaction of a brominated fluorescent molecule and Hoffer's chlorosugar.193 
These compounds were used as probes to study the complexation of nucleic acids with 
proteins and because of their fluorescent color tunability can potentially be used as 
biomedical diagnostic tools; they, however, do not form canonical base pairs.194-196 
 
Figure 13. Nucleosides with fluorescent base replacements 
1.3.2.2  Isomorphic Base Analogues 
Isomorphic nucleobases are heterocycles that bear a resemblance to natural 
nucleoside bases with respect to their overall size, hydrogen bonding capacity and ability 
to form Watson-Crick base pairs, Figure 14.181, 197 The 2-aminopurine 156, is possibly the 
most widely recognized fluorescent nucleoside, is an emissive isosteric adenosine 
analogue198  and has been used extensively in biochemical studies and assay 
development.199-200 Variations of 156, including modified 7-deaza and 8-aza-7-deaza 
analogues have been studied by Seela and coworkers as click chemistry substrates.201 
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Isomorphic pyrimidine analogues 5-methylpyrimidin-2-one 157 and pyrrolo-C 158 have 
been used to probe the RecA DNA complexes in E. coli202 and T7 RNA polymerases, 
respectively.   
 
Figure 14. Isomorphic purine and pyrimidine bases 
1.3.2.3  Pteridines 
Pteridines are fluorescent heterocycles that are comprised of two fused six 
membered rings instead of the natural configuration of a five membered ring fused to a 
six membered ring, Figure 15.203-204 All four pteridines analogues, mainly the guanosine 
analogue 159 and adenosine analogue 160, retained their overall absorption and emission 
characteristics when incorporated into ODNs; however, significant sequence dependent 
quenching was observed. Incorporating of these nucleoside analogues also typically 
resulted in destabilizing effects similar to a single base pair mismatch.205  
 
Figure 15. Examples of guanosine and adenosine pteridine analogues 
1.3.2.4  Extended Nucleobases 
Extending the conjugation of the natural bases by condensing an etheno bridge 
over the H-bonding face of the purines and pyrimidines has resulted in modified 
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nucleosides with favorable fluorescence properties,197 one of the first examples being 
1,N6-ethnoadenine 161, Figure 16.206-207 Another approach used by Leonard208 and 
Kool209 involves the introduction of an aromatic ring between the native pyrimidine and 
imidazole rings (e.g., 162). These benzo analogues deviate from the natural base's 
scaffold and thus cannot form Watson-Crick base pairs or be accommodated within a 
traditional Watson-Crick duplex.210 The addition of an additional aromatic ring at the 
periphery of the nucleobase (e.g., 163) represents another approach utilized by Godde 
and coworkers to monitor the binding of the HIV-1 Tat protein or of antisense 
oligonucleotides to the TAR RNA Stem-Loop.211 
 
Figure 16. Fluorescent extended nucleobases 
1.3.2.5  Conjugation to Fluorescent Molecules 
Linking nucleosides to fluorescent chromophores using a palladium mediated 
cross coupling reaction has been shown to give nucleoside analogues with high emissive 
properties, Figure 17.197 Several examples of fluorescent nucleoside conjugates are 
uridine conjugated to a pyrene212-213 164, phenanthroline214 165, and anthracene215 166  
which were used to study RNA-small molecule binding,216 to distinguish between perfect 
and mismatched complementary oligonucleotides214 and for genetic analysis to detect 
point mutations and SNPs,215 respectively. The hybridization properties of the native 
nucleosides are maintained because the fluorescent chromophores protrude into the major 
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groove of the double helix and can be used to detect the presence of abasic DNA sites.217 
 
Figure 17. Examples of uridine conjugated to a fluorophore 
1.4  Current Status on Drug Discovery Against Protozoal Parasite Trichomonas 
vaginalis and Tritrichomonas foetus 
1.4.1 Trichomonas vaginalis General Introduction 
Trichomonas vaginalis is a flagellated protozoan that causes the sexually 
transmitted disease trichomoniasis in humans. The most common symptoms in women 
are a frothy malodorous green discharge and edema.218 Colpitis macularis, also known as 
strawberry cervix, is a clinical sign of this disease, found during microscopic analysis of 
the tissue.219-220 The disease is not restricted to the vagina, and may also infect the urinary 
tract.221 Women who are infected during pregnancy are pre-disposed to premature rupture 
of placental membranes, early labor and low-birth infants.222 Furthermore, 
Trichomoniasis may also be associated with high-risk strains of human papillomavirus 
and cervical cancer in women.219 Trichomoniasis in men is largely asymptomatic, and 
these men are considered to be asymptomatic carriers of T. vaginalis; when men do 
manifest symptoms, they typically include urethral discharge and dysuria.219  
The standard treatment for trichomoniasis is 250 mg of metronidazole 167, given 
orally, three times a day for 7 days or a single 2 g dose, Figure 18. Metronidazole is 
administered as a pro-drug that enters the cell through diffusion and is activated in the 
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hydrogenosomes of T. vaginalis.223-224 Addition of a single electron to the nitro group of 
metronidzole leads to activation and a nitroso free radical is formed. Cellular response is 
rapid with cell division and motility ceasing within 1 hour and cell death within 8 h.225 
However, approximately 2.5-5% of all diagnosed cases of this disease are resistant at 
some level.226 Resistant infections are treated with larger doses of drug than the typical 
prescribed 2 g, and for a longer period of time,227 which is not ideal because patients are 
at risk for harsher side effects.    
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Figure 18. Standard treatment for trichomoniasis 
Clearly, new anti-protozoan agents are needed to treat resistant strains of T. 
vaginalis. Although many other nitroimidazoles have been tested against T. vaginalis, 
only metronidazole and tinidazole 168 are available in North America. Unfortunately, all 
nitroimidazoles have similar modes of activity,228 so resistance to metronidazole often 
includes resistance to the other nitroimidazoles.229 
1.4.2 Drug Discovery Against Trichomonas vaginalis 
Several studies have focused on the identification of new drugs against T. 
vaginalis and their targets; however, there are really no detailed and systematic studies on 
potential targets for new drug development. Many different strains of T. vaginalis exist 
and are used for biological and drug discovery studies. When screening potential 
inhibitors against the parasite, the effects of the inhibitors on various strains need to be 
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taken into account. Different strains of the same organism behave differently under the 
same pressures. A study of a small compound library of 3,4-dichloroaniline amides 
against two well-known strains of T. vaginalis (T1 and G3) illustrates this point.230 These 
twenty-one compounds, when screened for inhibitory activity, displayed different results 
with the compounds at the same concentration and performed under the same conditions. 
In this study, the most effective compound against both strains of the library was amide 
analogue 169 which possesses a tri-fluoromethyl group in the meta position, Figure 19; 
however, it's inhibitory effect is not as great at that shown by metronidazole.  
N
H
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169  
Figure 19. 3,4-Dichloroaniline amide as antiparasitic agents 
S-Adenosyl-L-homocysteine hydrolase is an enzyme that regulates S-adenosyl-L-
methionine-dependent methylation reactions. This enzyme catalyzes the reversible 
hydrolysis reaction of S-adenosyl-L-homocysteine (AdoHcy) into adenosine and 
homocysteine. In protozoan parasites, this enzyme exists and functions in a similar 
fashion to other known AdoHcy hydrolases (ADHY). Trypanosomes in particular possess 
a unique, highly-methylated 5’ cap on mRNA. In trypanosome protozoa, the pathways of 
methionine/AdoMet/decarboxylated AdoMet/AdoHcy and polyamine metabolism are 
closely related. These metabolic pathways have both been successfully targeted in the 
design of trypanocides.231 A small library of 5’-modified adenosine derivatives, including 
5’-deoxy-5’-(iodomethylene)-adenosine (e.g., 170 and 171), 6-N-cyclopropyl 172 and 5'-
oxime 173 analogues were screened and some of these molecules blocked growth of T. 
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vaginalis up to 95%, Figure 20.232 Although IC50 determination of the these compounds 
did not reveal values better than those for metronidazole, the results were highly 
suggestive of a critical biological role for ADHY hydrolase in this protozoan parasite. 
 
Figure 20. 5'-Modified adenosine analogues and related 6-N-cyclopropyl derivatives. 
Nitazoxinide (NIT) 174, a thiazolide, is a broad spectrum anti-protozoal pro-drug, 
Figure 21. Following oral administration, it is hydrolyzed to its active metabolite, 
tizoxanide 175.233 Benzologues, 176 and 177, of each of these drugs were prepared by 
Navarrete-Vázquez and tested for potency against T. vaginalis.234 Acetyl protected 
benzologue 159 showed nanomolar activity with an IC50 of 68 nM; however, it was 
significantly less potent than its parent drug NIT, metronidazole and TIZ. Analogue 177 
was also less potent than metronidazole, NIT and TIZ. A structure activity assay showed 
that the insertion of a benzene ring between the nitro and thiazole generated a new anti-
protozoal scaffold which can be further explored for cytotoxicity in other parasites.  
 
Figure 21. Nitazoxinide and Tizoxanide and their benzologues 
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A series of novel benzimidazole-pentamidine hybrids were also prepared by the 
Navarrete-Vázquez group and tested against T. vaginalis, Figure 22.235 An in vivo assay 
showed the 5–methoxy analogue 179 to be two times as active as the commonly used 
metronidazole and 23 times more potent than its parent drug pentamidine. The methyl 
analogue 180 and nitro 182 with a methoxy group at 2nd position in the benzene were 4 
and 5 times more potent than pentamidine, respectively. Lastly, unsubstituted analogue 
178, methyl analogue 180 and trifluoromethano analogue 181 exhibited the same activity 
than pentamidine. The results obtained by the authors are promising since several of the 
compounds tested showed activity greater than or comparable with the current used anti-
protozoal drugs.  
O O
178 R1 = H R2 = H
179 R1 = OCH3 R2 = H
180 R1 = CH3 R2 = H
181 R1 = CF3 R2 = H
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Figure 22. Benzimidazole-pentamidine hybids 
Adams et al.236 prepared a small library of aryl-functionalized and ferrocenyl 
monothiosemicarbazone compounds via a general Schiff-base condensation reaction, 
Figure 23. The thiosemicarbazone ligands act as bidentate chelating ligands that 
coordinate ruthenium(II) via the nitrogen of the imine group and the sulfur of the thione 
group. The ruthenium(II)-arene thiosemicarbazone complexes were evaluated for anti-
protozoal activity in the G3 strain of T. vaginalis. They determined that in order to have 
correct charge distribution and therefore parasitic inhibition, an electron withdrawing 
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group must be present. Thus, the most active compounds 185 and 186 contained a chloro-
aryl thiosemicarbazone moiety and exhibited IC50 values less than 10 µM.  
 
Figure 23. Aryl and Ferrocenyl-derived thiosemicarbazone ruthenium(II)-arene complexes. 
1.4.3 Tritrichomonas foetus General Introduction 
Tritrichomonas foetus, the feline and bovine counterpart of Trichomonas 
vaginalis, is a protozoal parasite that infects the bovine reproductive tract and causes 
infertility and occasional spontaneous abortions in cattle. It also affects the feline 
intestinal tract causing diarrhea. Currently there is no FDA approved treatment for 
animals infected with T. foetus. Therefore, the identification of potential molecules that 
could serve as the basis for new drug discovery against this important veterinary 
pathogen is warranted.237-239 
1.4.4 Drug Discovery Against Tritrichomonas foetus 
Currently there is no FDA approved treatment for animals infected with T. foetus; 
however, there are several notable studies include the effects of vinyl sulfone 
inhibitors,240 D-allose and D-psicose,241 benzimidazoles,242 hypoxanthine-guanine-
xanthine phosphoribosyltransferases,243 and ronidazole244 on T. foetus infections.  
Aronov et al. targeted the purine salvage enzyme hypoxanthine-guanine-xanthine 
phosphoribosyltransferase (HGXPRT) from the protozoan parasite Tritrichomonas foetus 
in their studies, Figure 24.243 A virtual library of substituted 4-phthalimidocarboxanilides 
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of type 187 was constructed using methods of structure-based drug design, and was 
implemented synthetically on solid support. Phenyl analogue 187 was used in 
combinatorial chemistry to produce a second more focused library of low micromolar 
inhibitors of HGXPRT. Bromo-phenyl analogue 188 was found to inhibit the growth of 
T. foetus in a concentration dependent manner with an ED50 of 2.8 µM. Interestingly, this 
inhibitory effect can be reversed by the addition of exogenous hypoxanthine 
demonstrating that parasitic protozoa lack the ability to synthesize purine nucleotides de 
novo, and rely on enzymes to salvage purine bases from the host.  
 
Figure 24. Inhibitors of Tritrichomonas foetus 
The trichomonicidal activity of benzimidazole analogues were evaluated by 
Carvalho and Gadelha against T. foetus, Figure 25.242 They found that mebendazole 190 
presented the highest inhibitory activity with of IC50 2.3 mM, when compared with 
albendazole 191 (IC50 9.4 mM) and thiabendazole 189 (IC50 142.6 mM). They also found 
that the inhibitory effects of the tested benzimidazole analogues 189 – 191 were 
irreversible. Furthermore, the treated cells demonstrated increased cellular volume, 
internalization of flagella, nuclear perturbations, multiplication of organelles and 
cytoplasmic vacuolization. Thus, demonstrating that mebendazole is a viable pathway for 
the therapy of bovine trichomoniasis.242  
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Figure 25. Benzimidazole analogues evaluated against T. Foetus 
Kather and coworkers evaluated the in vitro susceptibility of feline T. Foetus 
isolates against several known antimicrobial agents, Figure 26.245 They found that 
omeprazole 194 showed no effect at concentrations less than 80 µg/mL; however, 
ronidazole 192 and furazolidone 193 both showed activity similar to that displayed by 
metronidazole. Interestingly, 192 demonstrated a faster rate in the reduction of trophozite 
survival than metronidazole.   
 
Figure 26. Imidazole analogues evaluated against T. foetus 
The Arai group investigated the inhibitory effects of D-allose 195 and D-psicose 
196 on T. foetus, Figure 27.241 When either of these sugars were cultured in a medium 
including a dose of ED50 metronidazole, the parasite density was significantly less than in 
a medium of metronidazole alone. Although, it is known that the mechanisms of the two 
sugars used in this study are not the same, the authors hypothesize that they may interfere 
with the electron transport chain and thus reinforce the action of metronidazole. The 
dosage of metronidazole given could, therefore, be lowered and thus the development of 
drug resistance of protozoal parasites could be circumvented.  
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Figure 27. D-allose and D-psicose tested against T. foetus 
Nisha and coworkers described the Cu(I)Cl mediated synthesis of N-
propargylated-isatin-7-chloroquinoline conjugates (e.g., 197-199).246 The prepared bis-
conjugates were tested for their in vitro activity against T. foetus, Figure 28. Preliminary 
analysis revealed that the addition of the electron withdrawing chlorine atom (e.g., 198, 
IC50 11.3 µM) enhanced the activity profile over the addition of an electron donating 
methyl group (e.g., 199, IC50 24.5 µM) or unsubstituted parent scaffold 197 (IC50 22.2 
µM). Studies with human cell lines showed that these analogues are devoid of virtually 
all cytotoxic activity and thus are an excellent starting point for the synthesis of new 
pharmacological scaffolds against T. foetus.  
 
Figure 28. N-propargylated-isatin-7-chloroquinoline conjugates tested against T. foetus 
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2 Research Objectives 
The first objective of this dissertation was to develop and study in vitro and in 
vivo the novel click chemistry of azido modified purine and pyrimidine bases with 
cyclooctynes, Figure 29. These analogues were intended to be used (1) to explore the 
strain promoted click chemistry (SPAAC) of azido nucleosides at the monomer level, (2) 
to investigate the properties of click adducts for the fluorescent imaging of live cells and 
(3) to explore the sparsely known strain promoted click chemistry on azido modified 
DNA or RNA.  
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Figure 29. Azido modified nucleosides for SPAAC 
Unsubstituted nucleosides are typically weakly fluorescent and therefore not 
suitable for fluorescent tagging in living systems. However, direct conjugation of a 
triazole ring with a nucleobase at the C2, C5 and C8 position results in nucleoside 
derivatives with fluorescent properties. Relatively few studies examples have explored 
the exploitation of the inherent fluorescent properties of modified purine nucleosides as 
fluorescent reporters. Furthermore, visualization of living cells using pyrimidine based 
click adduct nucleosides without the use of fluorescent reporters has yet to be described. 
Thus, the proposed synthetic approach targets the most underdeveloped synthetic 
click precursors in nucleosides; azide modified nucleobases. The underdeveloped strain 
promoted azide-alkyne cycloaddition (SPAAC) in nucleosides will be explored to obtain 
53 
 
fluorescent triazole adducts. The proposed click substrates are designed having the azido 
group on the heterocyclic base which are suitable for eventual conjugation with 
cyclooctynes designed by Bertozzi, Boons, or van Delft.  
The click reaction between non-fluorescent azido nucleosides (e.g., 200-202) and 
a cyclooctyne directly should yield a triazole product (e.g., 203-205) with fluorescent 
properties without the need for additional modification to achieve visualization. I hence 
endeavored to investigate the fluorescent properties of click adducts in live cancer cells 
using fluorescent microscopy. Fluorescence lifetime imaging microscopy (FLIM) will 
also be used to characterize the in vivo lifetime of several of the synthesized triazole 
adducts in living cancer cells. The formation and presence of the desired triazole 
analogues will also be determined in living cancer cells by comparing the observed in 
vivo and in vitro lifetime values. 
 
Figure 30. Fluorescent click adducts for live cell imaging 
Methods for the synthesis of azido-nucleobase modified 5'-triphosphates and the 
possibility of performing click chemistry on such modified nucleotides at the 
polynucleotide level will also be explored. The desired triphosphates could be 
incorporated into RNA and DNA chemically or enzymatically with the aid of 
polymerases. Azido modified nucleosides are typically incompatible with solid phase 
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synthetic methods because of the known reduction reaction between the azide moiety and 
the P(III) present in the requisite phosphoramidite reagent. When the azido modified 
DNA or RNA is coupled through a click reaction with a cyclooctyne, a fluorescent 
oligonucleotide will be formed.  The fluorescence can be utilized for direct visualization 
of native DNA or RNA in live cells without the need for the traditional fluorescent dyes.  
The second objective of my dissertation explores the application of the click 
chemistry methodology established in the first objective of my dissertation to study the 
cellular targets in parasites and bacteria. Thus, initially the anti-protozoal properties of a 
library of purine and pyrimidine nucleosides with base and sugar modifications would be 
evaluated against protozoan parasites Trichomonas vaginalis and Tritrichomonas foetus. 
Following characterization of cytostatic profiles, promising analogs will be modified with 
an azide group on its nucleobase. The resulting adducts of a click reaction between the 
azido modified substrate and cyclooctyne can be used for investigation. Their inherent 
fluorescent properties could be exploited to study their mechanism and cellular targets in 
parasite containing cells via fluorescent microscopy or biotin and streptavidin tagging.247  
The third objective of this dissertation was to study the transfer of the protruding 
methyl group present from S-adenosyl-L-methionine (SAM), when SAM is in the 
tRNA(m1G37)methyltransferase (TrmD) binding pocket. I endeavored to synthesize 
constrained and activated S-adenosyl-L-methionine (SAM) analogues which mimic the 
naturally occurring bent conformation of SAM in the TrmD binding pocket. The bicyclic 
nucleoside derivatives having 9, 10, or 11 membered rings bridging from the C5’ 
thioether to either the 3' or 2' OH groups could be undertaken using several methods 
including lactonization, lactamization or metathesis methods. These cyclic analogues 
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could be potential inhibitors of tRNA and can be utilized as probes to study the transfer 
of the methyl group. To probe the mechanism of action of the TrmD enzyme an analogue 
with an EnYn group on the sulfur instead of a methyl can be prepared. The EnYn 
analogue can be used in reactions with methyltansferases, enzymatic tagging and click 
chemistry for eventual introduction of a fluorophore.   
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3 Results and Discussion 
3.1  Design, synthesis and click chemistry of C2 and C8 azido modified purine and 
C5 azido modified pyrimidine analogues.  
Typically purine nucleosides can be conveniently modified at the C2, C6 and C8 
positions and pyrimidine nucleosides at C5 or C6 positions because these modifications 
remain in the major groove and do not affect the formation of the DNA duplex.248 Even 
bulky groups introduced in these positions are typically well tolerated, making them one 
of the best sites for derivatization. Sugar modifications on nucleosides normally change 
the characteristics of the parent compound making them not ideal of tagging. 
Furthermore, tagging at the 3' and 5' hydroxyl groups impedes phosphorylation by native 
kinases possible changing the mechanism of action of the parent drug. Thus, the initial 
targets of my dissertation were the synthesis of C2 and C8 position azido modified 
purines and C5 modified pyrimidine nucleosides and nucleotides which are suitable for 
further modification via the SPAAC. Introduction of a triazole ring to either the purine or 
pyrimidine rings results in nucleosides with fluorescent properties that can be used for 
fluorescent microscopy.  
3.1.1 SPAAC of 8-Azidoadenine Nucleosides and Nucleotide 
3.1.1.1 Preparation of Substrates 
The 8-azidoadenine nucleoside analogues 200-203 have been traditionally 
prepared using the methodology as reported by Holmes.249 I found, however, that 
bromination of adenosine 206 with 1.75 equivalents of 1,3-dibromo-5,5-
dimethylhydantoin (DBH) in DMF250 gave the corresponding 8-bromo derivative 210 
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in 45% yield after column chromatography. Further treatment of bromo analogue 210 
with sodium azide in DMF at 65 °C for 12 h gave 8-azido derivative 200 in good 
yields, Scheme 40. Tracking the progress of this azidation can be troublesome 
because the Rf of the bromo and azido analogues are similar; therefore, the progress 
of the reaction must be tracked by integrating disappearance of H2 of 210 at 8.10 ppm 
and appearance of H2 at 8.09 ppm for product 200 in the 1H NMR spectra. The arabino 
analogue 214, fluoro-arabino analogue 215 (see section 3.4.3 for detailed discussion) and 
deoxy analogue 216 were all prepared in a similar manner.  
 
Scheme 40. Synthesis of 8-Azidoadenine Nucleosides 
3.1.1.2 SPAAC Reaction 
The reaction between the equivalent amounts of 8-azidoadenosine249 200 and 
symmetrically fused cyclopropyl cyclooctyne162 217 occurred efficiently in an aqueous 
solution of acetonitrile (ACN) at ambient temperature (3 h) to produce a triazole 203 in 
96% yield after silica gel chromatography, Scheme 41.  I was also able to purify the 
reaction by direct injection into the HPLC; thus, the entire reaction mixture was injected 
into a into a Phenomenex Gemini semi-preparative RP-C18 column (5µ, 25 cm X 1 cm) 
via 2 mL loop and eluted with isocratic mobile phase mixture 17% CH3CN in H2O at a 
flow rate = 2 mL/min to give 203 (94%) as a white solid tR = 4.5 – 8.2 min. The reaction 
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also occurred efficiently in MeOH, EtOH and Opti-MEM cell culture media, once again 
showing that the click reaction can proceed efficiently in any aqueous or organic media 
as long as both substrates demonstrate suitable solubility in the reaction solvent.  
The reaction between 8-azido-9-(β-D-arabinofuranosyl)adenine 214 or 8-azido-2'-
deoxy-2'-fluoro-9-(β-D-arabinofuranosyl)adenine 215 and 217 (OCT) also proceeded 
smoothly (3 h, rt) in ACN/H2O (3:1) to give the corresponding triazole products 219 and 
221, quantitatively. Both of these reactions were easily monitored by TLC since the 
product formed a more polar spot with a distinctive blue fluorescent color. Analogous 
treatment of 8-azido-2'-deoxyadenosine 216 with 217 gave the click product 222 (97%), 
the crude reaction mixture was passed through a 0.2 μm PTFE syringe filter, and then 
similarly injected into a semipreparative HPLC column (Phenomenex Gemini RP-C18 
column; 5 μ, 25 cm × 1 cm) via a 2 mL loop. The HPLC column was eluted with an 
isocratic mobile phase mixture of 17% CH3CN/H2O at a flow rate of 2.0 mL/min to give 
22 (77%) as a mixture of inseparable regioisomers (tR = 13.0 – 16.2 min). The reaction of 
azide 201 with biotin modified OCT 235 afforded adduct 238 (100%, 57% purified 
yield). The HPLC purification and 1H NMR of this compound was quite complex 
because of the large biotin modification; however, biotin tagging using click chemistry is 
important because the biotin-avidin interaction is commonly used by biochemists to 
detect and/or purify proteins and DNA. A summary of the click reaction conditions 
between the 8-azidoadenine nucleosides and cyclooctynes can be seen in Table 2. 
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Scheme 41. SPAAC on 8-Azido Adenine Nucleosides 
The kinetic analysis presented in Figure 31A showed that click reaction between 
200 and 217 initially occurred very rapidly (60% conversion in 20 minutes) and then 
plateaued forming little new product after 70 minutes. Sequential 1H NMR scans of this 
reaction showed that it proceeded without the formation of any byproducts. The profile 
for the reaction was measured by integrating disappearance of H2 of 1 at 8.07 ppm and 
appearance of H2 at 8.28 ppm for product 7 on 1H NMR spectra. The reaction has a 
second order rate constant of 0.11 M-1s-1, Figure 31B, which is similar to the previously 
published reaction of OCT 217 with benzyl azide.162 
 
Figure 31. (A) The kinetics profile of the SPAAC of a 23 mM solution of 8-azidoadenosine 200 and cyclooctyne 217  
in ACN-d6/D2O (3:1, v/v) as monitored by 1H NMR. (B) The rate plot for SPAAC of 200 and 217.  
The second order rate constant was calculated by plotting 1/[azide] as a function of time. Data are plotted to within 
90% conversion to the triazole products. 
0
20
40
60
80
100
0 50 100 150
%
 C
on
ve
rs
io
n
Time in Minutes
y = 0.1058x + 0.043
R² = 0.9918
0
5
10
15
20
0 50 100 150
1/
[a
zi
de
]
Time in Minutes
(A)             (B) 
60 
 
The click reaction of 8-azidoadenosine 200 with more complex cyclooctynes 
including strain modulated dibenzylcyclooctyne251 223 or electronic modulated 
monofluorocyclooctyne 227 in MeOH produced the triazoles modified with a terminal 
amine 224, Scheme 42, or typically "reactive" N-hydroxysuccinimide (NHS) ester 228, 
quantitatively as 1:1 mixture of regioisomers, Scheme 43. The reaction of 200 with 223 
was sluggish and required overnight heating at 50 °C, while coupling of 200 and 227 was 
completed at ambient temperature overnight.  Goddard and Bertozzi noted that although 
the aryl ring fusion may enhance the cyclooctyne ring strain; however, the sluggish 
reactivity of DBCO 223 with azides can be attributed to the "flagpole" hydrogen atoms 
ortho to the aryl/cyclooctyne ring junction which decrease reactivity by steric 
interference with the azide in the transition state.44, 252  
Furthermore, 8-azidoadenine nucleosides 201 or 203 react efficiently with 223 to 
give the corresponding triazole products 225 and 226. Even though 223 is not 
immediately soluble in acetonitrile and water (3:1 v/v), overnight heating at 50 °C of 200 
with 223 similarly afforded 224 in high yields. Thus, after 16 h, the crude reaction 
mixture was purified using RP-HPLC. The HPLC column was eluted with an isocratic 
mobile phase mixture of 40% CH3CN/H2O at a flow rate of 1.0 mL/min to give 224 as a 
mixture of inseparable regioisomers tR = 15.5 – 23.0 min.  
 
Scheme 42. SPAAC on 8-Azidoadenosine and Analogues with Dibenzyl Cyclooctyne 
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Scheme 43. SPAAC on 8-azidoadenosine with Monofluoro Cyclooctyne 
Since click chemistry for labeling oligonucleotides is an emerging field,103 I 
established a protocol for the SPAAC of azido base modified nucleotides with 
cyclooctynes. Thus, the click reaction of commercially available 8-azidoadenosine 5'-
triphosphate tetralithium salt 229 and symmetrically fused cyclopropyl cyclooctyne 217 
(OCT) in aqueous ACN efficiently gave the triazole product 230 in 92% yield, Scheme 
44. The reaction was conducted at ambient temperature in an NMR tube, with no stirring, 
inside of the NMR spectrophotometer to study the kinetic profile of the reaction; 
therefore, the reaction would have probably occurred faster under typical reaction 
conditions that include constant vigorous stirring.  
 
Scheme 44. SPAAC on 8-azidoadenosine 5'-triphosphate tetralithium salt 
A 1H NMR kinetic analysis of the click reaction between is depicted in Figure 32 
and showed that reaction also occurred rapidly (46% in 20 minutes, 87% in 2 h) and did 
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not yield any undesired byproducts. The kinetic study shows a similar reaction profile 
and rate constant to the reaction between azide 200 and cyclooctyne 217 which initially 
occurred very rapidly and then plateaued forming little new product after 70 minutes. 
Thus, this reaction also has a second order rate constant of 0.07 M-1s-1, Figure 32B. 
 
 
 
Figure 32. (A) Monitoring of the 1H NMR kinetic profile of the reaction between 8-azidonucleotide 229 and 
cyclooctyne 217. (B) The rate plot for SPAAC of 229 and 217. 
The second order rate constant was calculated by plotting 1/[azide] as a function of time. Data are plotted to 
within 90% conversion to the triazole products. 
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Azide Cyclooctyne Product Time Temp Solvent Yield [%]a 
200 217 203 3 h rt ACN/H2O (3:1) 98 (96)b 
200 217 203 3 h rt MeOH 98 
200 217 203 3 h rt EtOH 98 
200 217 203 3 h rt Cell Culture Media 98 
214 217 219 3 h rt ACN/H2O (3:1) 100 (93) 
214 218 220 3 h rt ACN/H2O (3:1) 100 (71)b 
215 217 221 2 h rt ACN/H2O (3:1) 98 
216 217 222 3 h rt ACN/H2O (3:1) 100 (96)b 
200 223 224 16 h 50 °C ACN/H2O (3:1) 100 (98)b 
214 223 225 16 h 50 °C MeOH 100 (95)b 
216 223 226 16 h 50 °C MeOH 100 (95)b 
200 227 228 16 h rt MeOH 98 
a Based on 1H NMR. Yields for the products purified on a silica gel column are in parenthesis. 
b Purified by RP HPLC 
Table 2. Summary of the click reaction conditions between 8-azido adenine nucleosides and cyclooctynes 
3.1.2 SPAAC of 2-Azidoadenosine  
The CuAAC for the introduction of 1,2,3-triazole at the C8 position or on the 
sugar in the adenosine scaffold is very popular; however, CuAAC on 2-azido adenine 
nucleosides (e.g., 201) is sparsely known with very few examples shown in literature.105-
107, 253 Moreover, the SPAAC reaction of 2-azidoadenosine 201 is currently unknown.  
3.1.2.1 Preparation of Substrates 
The 2-azidoadenosine 201 can be prepared using a modified version of the 
Schaeffer procedure, Scheme 45,104, 254 or is commercially available. Thus, commercially 
available 2,6-dichloropurine 232 is coupled to 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribose 
231 in the presence of stannic chloride to give the corresponding 2-chloro modified 
nucleoside 233 which after treatment with hydrazine and sodium nitrite in an acid 
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solution gives target azide 201, Scheme 45. Cladribine 233 is commercially and can also 
be used as a convenient precursor for azide 201. 
 
Scheme 45. Synthesis of 2-azidoadenosine254 
3.1.2.2 SPAAC Reactions 
The adenosine modified with azido group at the C2 position 201 also undergoes 
SPAAC reaction efficiently. Thus, 201 reacts with cyclooctyne 217 in aqueous media at 
ambient temperature for 3 h to yield a lower moving spot by TLC. The 1H NMR showed 
quantitative conversion to click adduct 234 without the need for further purification, 
Scheme 46. The reaction was also tracked with the help of the UV/Vis 
Spectrophotometer, Figure 33. The UV/Vis profile of starting azide 201 was quite 
complex exhibiting 2 peaks and 2 valleys including characteristic azido purine peak at 
λmax 269 nm (ε 12 617). Throughout the course of the click reaction a hypochromic shift 
was seen until the starting material 201 had completely converted to adduct 234 λmax 260 
nm (ε 10 700). 
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Figure 33. A. UV/Vis profile of 2-azidoadenosine 201, B. UV/Vis profile of adduct 2-OCT-adenosine 233 
On the other hand, the SPAAC reaction of 201 with DBCO 223 proceeded 
smoothly to give the more polar triazole 235. The purification of the reaction product was 
significantly more challenging and required HPLC. Thus, the crude reaction was passed 
through a 0.2 μm PTFE syringe filter, and then injected into a semipreparative HPLC 
column (Phenomenex Gemini RP-C18 column; 5 μ, 25 cm × 1 cm) via a 2 mL loop. The 
HPLC column was eluted with an isocratic mobile phase mixture of 40% CH3CN/H2O at 
a flow rate of 2.0 mL/min to give 235 in an 85% isolated yield as a mixture of 
inseparable regioisomers tR = 13.0 – 16.2 min. A summary of the click reaction 
conditions between the 2-azidoadenosine and cyclooctynes can be seen in Table 3. 
 
Scheme 46. SPAAC on 2-Azidoadenosine 
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Azide Cyclooctyne Product Time Temp Solvent Yield [%]a 
201 217 233 2 h rt ACN/H2O (3:1) 100 
201 223 234 16 h 50 °C MeOH 98 (85)b 
a Based on 1H NMR. Yields for the products purified on a silica gel column are in parenthesis. 
b Purified by RP HPLC 
Table 3. Summary of the click reaction conditions between 2-azidoadenosine and cyclooctynes 
3.1.3 SPAAC with 5-Azidouracil Nucleosides 
3.1.3.1 Preparation of Substrates 
The 5-azidouridine 202 is commercially available or can be prepared from parent 
nucleoside uridine 236. Thus, 236 was treated with 0.55 equivalents of DBH in DMF for 
10 minutes to afford less polar 5-bromo analogue 238.250 Conversion to the 5-amino 
analogue proceeded as described by Gourdain et al.255 by heating with liquid ammonia at 
70 °C overnight in a high pressure vessel. In the morning the reaction was cooled to -78 
°C and the pressure was released allowing the ammonia to slowly boil off, leaving 5-
amino derivative 240 as an oily brown residue. Direct treatment of amine 240 with triflic 
anhydride and sodium azide in a Sandmeyer azidation gave target azide 202, Scheme 47. 
Treatment of 2'-deoxyuridine 237 in a similar reaction sequence of bromination, 
amination and Sandmeyer azidation gave the highly photolyzable 5-azido-2'-
deoxyuridine 242. The latter aromatic substitution reaction including all post reaction 
manipulations must be run in the dark in order to avoid the known photolysis of 242 
caused by UV irradiation.113  
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Scheme 47. Synthesis of 5-zzido Uracil Nucleosides 
3.1.3.2 SPAAC Reactions 
The click reaction between 5-azidouridine256 202 and several cyclooctynes 
including 217, 218, 223 or 227 proceeded quickly and very effectively yielding the 
corresponding click adducts 244, 245, 247 and 248. Thus, treatment of 5-azidouridine 
202 with hydroxyl modified cyclooctyne 217 in ACN:H2O  mixture (3:1, v/v) afforded 
244 in 3 minutes at ambient temperature as a more polar spot on the TLC, Scheme 48. 
The crude reaction mixture was passed through a 0.2 μm PTFE syringe filter, and then 
injected into a semipreparative HPLC column (Phenomenex Gemini RP-C18 column; 5 
μ, 25 cm × 1 cm) via a 2 mL loop. The HPLC column was eluted with an isocratic mobile 
phase mixture of 20% CH3CN/H2O at a flow rate of 2.0 mL/min to give 23 (5.8 mg, 
77%) tR = 5.2 – 8.0 min. Furthermore, treatment of azide 202 with biotin modified 
cyclooctyne 218 for 3 minutes at ambient temperature gave the corresponding triazole 
245 as a white solid. Analogous treatment of 5-azidouridine 202 with DBCO-NH2 223 or 
NHS modified MFCO 227 in methanol at ambient temperature afforded complete 
conversion to triazoles 247 or 248 in less than 15 minutes, Figure 34.  
The click reaction of the highly photolyzable 5-azido-2'-deoxyuridine255 242 with 
cyclooctyne 217, in the ACN/H2O/MeOH (3:1:1 v/v/v) gave corresponding triazole 
product 246 in excellent yield, Scheme 48. MeOH (~20%) must be added to the reaction 
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mixture to solubilize the starting nucleoside and allow the reaction to proceed efficiently. 
Additionally, the click reaction must be run in the dark in order to avoid photolysis of 
242 caused by UV irradiation.113 A summary of the click reaction conditions between the 
5-azidouracil nucleosides and cyclooctynes can be seen in Table 4. 
 
Scheme 48. SPAAC on 5-azido Uracil Nucleosides 
 
Figure 34. 5-Triazo-yl Uracil Click Adducts 
Azide Cyclooctyne Product Time Temp Solvent Yield [%]a 
242 217 244 5 min rt ACN/H2O (3:1) 95 (77)b 
242 218 245 3 min rt ACN/H2O (3:1) 98 
243 217 246 15 min rt ACN/H2O/MeOH (3:1:1) 100 
242 223 247 15 min rt MeOH 100 (77)b 
242 227 248 12 min rt MeOH 100 
a Based on 1H NMR. Yields for the products purified on a silica gel column are in parenthesis. 
b Purified by RP HPLC 
Table 4. Summary of the click reaction conditions between 5-azidouridine or 5-azido-2'-deoxyuridine and cyclooctynes 
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3.1.4 Fluorescence and Physical Properties of Triazole Adducts 
Unsubstituted nucleosides are typically weakly fluorescent;257-260 however, 
substitution at the C2 and C8 position of the purine ring or C5 of the pyrimidine ring with 
fluorogenic moieties results in nucleosides with fluorescent properties.126, 261 While the 8-
azidoadenosine 214 has no fluorescence, the click adduct 203 with triazole ring attached 
directly to the imidazolyl ring of purine via nitrogen atom emits at 300–500 nm with the 
maximum emission at 376 nm (Φem = 0.6%, B = 0.13 M-1cm-1). Similarly, 5-azidouridine 
202 exhibits no noticeable fluorescence, whereas the triazole product 244 shows 
moderate emission between 285 nm and 550 nm with two emission peaks at 320 nm and 
450 nm (Φem = 1.1%, B = 0.12 M-1cm-1). Interestingly, this triazole product showed an 
excitation maxima at 388 nm which was mainly observed in alkaline phosphate buffer 
(Figure 35d). A more moderate change in the absorption spectra was observed in MeOH 
and DMSO indicating a ground state deprotonation of the pyrimidine triazole scaffold. 
The click adduct 235 of the 2-azidoadenosine and DBCO exhibited the highest 
fluorescence quantum yield (10.6%), the largest stokes shift (133 nm) and was the 
brightest (1.74 M-1cm-1) of the library of compounds that were prepared and tested, 
Figure 35. The 2-OCT-adenosine adduct 234 was the second brightest compound (0.38 
M-1cm-1) and exhibited the second largest extinction coefficient, Table 5.  
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The effect of solvent polarity was explored for derivatives 203, 219, 222, 224, 
228, 234, 235, 244 and 248 in DMSO and phosphate buffer pH 7.0, Figure 36. We 
observed a 10 nm and 17 nm bathochromic shift for 222 and 235 upon increasing solvent 
polarity (from DMSO to phosphate buffer at pH 7.0). Compound 244 showed a more 
complex spectra upon increase in solvent polarity, with peaks at 324 nm and 440 nm 
undergoing bathochromic shifts of 10 nm and 5 nm. The uncorrelated shift in emission 
likely arises from multiple glycosyl bond conformers of 23 each exhibiting different 
photophysical properties.  Manderville found that compounds with different glycosyl 
bond conformations (syn vs anti) have different photophysical properties.262-263 Thus, in 
solution 244 could exist as a monomer with a lifetime of 5 ns, but in a cell, π stacking 
with neighboring compounds could cause a broadening in the excitation spectra and a 
population with the shorter lifetime.  The amplitude of the fluorescence emission was 
increased in DMSO for the uracil compounds, when compared to the intensity in MeOH 
and buffer. On the other hand, the intensity of the adenine derivatives was enhanced in 
Figure 35. Normalized fluorescence emission, absorption and excitation spectra for the selected click adducts: a) 244,
b) 222, and c) 235 in MeOH; (d) The pH effect on the excitation spectra of 244 in phosphate buffer. 
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MeOH and quenched in buffer, with exception of analogues 203 and 224 which were 
enhanced in DMSO. The observed increase in fluorescence intensity in an aprotic solvent 
(i.e., DMSO) for the uridine derivatives correlates with the observed ground state 
deprotonation of the uracil triazole moiety.  The solvent effect on 203 and 224 show 
distinct responses despite their similar structures, indicating that removal of the hydroxyl 
group at C2’ likely induces a change in electron delocalization. Furthermore, introduction 
of a triazole ring at either the C2 or C8 positions likely causes a significant change in 
conformation (syn vs anti) thus changing the solvent sensitivity of the fluorophore, as 
shown by the OCT derivatives 203 and 234 and DBCO derivatives 224 and 235.  
 
 
   
Figure 36. Fluorescence intensity of click adducts in DMSO, MeOH and 50 mM phosphate buffer at pH 7 (PB7)  
solvents: a) 203, b) 219, c) 222, d) 224, e) 228, f) 234, g) 235, h) 244 and i) 248. 
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Figure 37. Absorption spectra of click adduct 244 in 50 mM phosphate buffer at pH 5 and 9. 
All triazole products showed a complex fluorescence decay lifetime, with at least 
a triple discrete model needed to obtain a satisfactory fit (Figure 3), except analogue 219 
which showed a biphasic decay. A fast lifetime of 0.1 ns to 0.6 ns was present in all 
compounds (Table 2). We hypothesize that the fast decay is likely the result of 
fluorescence decay of the adenine or uracil heterocyclic bases. In addition, 0.8 ns - 2.3 ns 
and 4.1 ns - 7.8 ns lifetime was recovered for all compounds, with 247 showing the 
longest lifetime (7.8 ns). The fractional contribution of each lifetime also varied among 
all triazole products; however, 222 (19%), 235 (40%) and 244 (38%) showed the largest 
contribution of the long lifetime (τ3). The longest average lifetime was observed for 235 
(2.8 ns), followed by 244 (2.7 ns), 247 (2.7 ns) and 222 (1.6 ns), Table 5. The recovered 
average fluorescence lifetime of the most fluorescent compounds is comparable to the 
lifetimes of current fluorescent proteins widely used in fluorescence lifetime imaging 
(FLIM),264 indicating the potential utility of these fluorescent nucleoside analogs in FLIM 
for dynamic measuring and tracking of signaling events inside single living cells. 
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203 219 222 224 228 234 235 244 247 248 
ߝ௠௔௫(ܯିଵܿ݉ଵ) 21100 7500 8200 6000 6400 9100 6400 10100 7300 7100 
ߣ௠௔௫(ܾܽݏ)௔(݊݉) 270 273 272 276 271 261 263 270 276 269 
ߣ௠௔௫(݁ݔܿ)௔(݊݉) 280 278 290 293 288 270 295 276 312 - 
ߣ௠௔௫(݁ݔܿ)௔,ௗ(݊݉) 309 - - 360 - 329 - 388 370 - 
ߣ௠௔௫(݁݉݅)௔(݊݉) 392 390 397 440 399 395 428 312 361 327/412 
ߣ௠௔௫(݁݉݅)௕(݊݉) 376 384 392 429 397 375 422 324/440 - 331/419 
ߣ௠௔௫(݁݉݅)௖(݊݉) 403 400 402 452 399 405 439 334/445 - 339/434 
ܵݐ݋݇݁ݏ ݏℎ݂݅ݐ ௔(݊݉) 83 112 107 80 111 66 133 44/62 49 58 
Φி௔ 0.006 0.006 0.014 0.017 0.006 0.02 0.106 0.011 0.013 0.009 
ܤݎ݅݃ℎݐ݊݁ݏݏ௔(ܯିଵܿ݉ଵ) 0.13 0.11 0.25 0.27 0.10 0.38 1.74 0.12 0.09 0.06 
߬ଵ௔(݊ݏ) 0.10 0.60 0.10 - 0.10 0.30 0.10 0.30 0.30 - 
߬ଶ௔(݊ݏ) 0.80 4.90 0.90 - 0.90 1.0 2.0 1.30 2.30 - 
߬ଷ௔(݊ݏ) 5.90 - 5.60 - 5.30 5.80 4.10 5.70 7.80 - 
߬௔௩௘௥௔௚௘(݊ݏ) 0.70 1.60 1.60 - 1.20 0.80 2.80 2.70 2.70 - 
ଵ݂௔(%) 0.63 0.77 0.28 - 0.46 0.64 0.02 0.22 0.11 - 
ଶ݂௔(%) 0.30 0.23 0.53 - 0.39 0.30 0.58 0.39 0.78 - 
ଷ݂௔(%) 0.07 - 0.19 - 0.15 0.05 0.40 0.38 0.11 - 
a In MeOH. b In DMSO. c In 50 mM phosphate buffer pH 7.0. d Second maxima observed at the red edge of the 
excitation spectra.  
Table 5. Photophysical data for the selected triazole adducts. 
3.2 Application of Click Chemistry with Azido Nucleosides To Living Cell 
Fluorescent Imaging 
Taking advantage that the click reaction between non-fluorescent azido 
nucleosides and cyclooctynes directly yields triazole products with fluorescence without 
necessity for additional modification for visualization, we have tested their application to 
in vivo studies and have demonstrated the viability of these reactions in living cells. 
3.2.1 Cell Permeability Assay 
The absorption of oral drugs is mainly determined by their ability to permeate 
through the GI tract and into the bloodstream. Faller et al. has shown a correlation 
between drug permeation across an alkane liquid membrane immobilized between two 
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aqueous phases and percent absorption in humans. A parallel artificial membrane 
permeation assay (PAMPA), was used to predict permeability of selected azides 201, 214 
and 216 and triazoles 222, 235 and 244. The results showed that approximately 20% of 
each compound was passively permeating in through the cellular membrane, Table 6. 
Typically, however, nucleoside transport proteins are also responsible for the cellular 
uptake of natural and modified nucleosides;265 thus, although outside of the scope of this 
dissertation, these proteins might play a significant role in the uptake of these nucleoside-
based theranostics.  
Compound % Fraction Absorbed Log Pe (cm/s)a 
201 22 -0.5 
214b 18 -0.5 
216 20 -0.5 
222 21 -0.3 
235 22 -0.03 
244 20 -0.4 
 aLog of the effective permeability coefficient, Pe (cm·s −1 ), as assessed by a parallel artificial membrane permeability 
assay (HDM-PAMPA); bPermeability is independent of concentration as shown by assays performed at 150 µM and 75 
µM concentrations.   
Table 6. Cellular permeability data for the selected azides and triazole adduct 
3.2.2 Cytotoxicity Assay 
A cell toxicity assay was used to determine the non-toxic dose of triazoles 219 
and 244 in MCF-7 cells, Figure 37. The effect of a single dose of azide 214 and azide 202 
together with cyclooctyne 217 on the survival of MCF-7 cells cultured in a 96-well plate 
with DMEM/F12 media was assessed for a 24 h period. Under these conditions MCF-7 
cells were subjected to the MTT assay that measured the ability of cells to reduce the 
tetrazolium dye. We measured activity of MCF-7 cells at the most active part of the cells 
growth phase 24 h after cell seeding (50% confluency). The y-axis of the dose-response 
graph represents cell viability correlated to metabolic activity. As shown in the dose-
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indistinguishable in cells incubated without azide 214 (Figure 39 panels C and D) or 
cyclooctyne 217 (Figure 38 panels A and B).  
 
Figure 39.  Fluorescence microscopy images  
Brightfield photos (Panels A, C and E) and phase photos (Panels B, D and F) of live MCF-7 cells: (Panels A, B)  
MCF-7 cells after incubation with 8-azido-9-(β-D-arabinofuranosyl)adenine 214 (100 µM) as a negative 
control; (Panels C, D) MCF-7 cells after incubation with cyclooctyne reagent 217 (100 µM) as an another 
negative control; (Panels E, F) MCF-7 cells containing azide 2 after incubation with cyclooctyne 5 in cell 
culture media. Scale = 40 µm 
A concentration-dependent experiment with Lipofectamine was also performed in 
live MCF-7 cells, which showed an increase in fluorescence intensity as the 
concentration of azide 214 increased, Figure 40.  
 
 
Figure 40. Dose response studies 
with 12.5 µM to 200 µM (shown in white on each panel) of azide 242 and 125 µM cyclooctyne 217.  Scale = 40 µm 
Furthermore, an in vivo assay of the click reaction between 5-azidouridine 242 and 
cyclooctyne 217 was performed. As expected, a direct light up of the live MCF-7 cells 
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was observed as click product 244 formed with fluorescence increasing as the 
concentration of azide 202 increased, Figure 41. 
 
                         
Figure 41. Dose response studies  
with 12.5 µM to 200 µM (shown in white on each panel) of azide 244 and 125 µM cyclooctyne 217. Scale = 40 µm 
 
The data from our fluorescent microscopy studies showed that the click reaction 
successfully occurred in MCF-7 cells treated with nucleosides and Lipofectamine at a 
concentration range from 12.5 - 200 µM as evidenced by the fluorescence of compounds 
219 (Figure 40) and 244 (Figure 41). The fluorescence of both compounds occurred 
throughout the cytosol and nuclear regions which we suspect to be influenced by the 
Lipofectamine transfection reagent. The usefulness of these azido derivatives for imaging 
of nucleoside-based drugs in living cells by direct fluorescence light-up will depend on 
cell viability; however, the dose of Lipofectamine used in these experiments showed 
significant changes to the morphology of cells. The MCF-7 cells displayed signs of cell 
swelling and cytolysis as shown in the fluorescence and phase-contrast photos (Figure 38 
Panels E and F). On the basis of our fluorescent imaging data, we showed that click-
chemistry robustly occurred inside the cells via liposome delivery. Thus, we decided to 
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extend our studies to show that these azido nucleosides are able to undergo click-
chemistry with cyclooctynes inside the cells without the aid of Lipofectamine.  
The click chemistry between 8-azido-arabino-Ado 214 and cyclooctyne 217 was 
therefore carried out in MCF-7 breast cancer cells.  The MCF-7 cells were incubated for 
3 h at 37 °C in a CO2 incubator with 214 (1 µM). The click reaction commenced via the 
addition of cyclooctyne 217 1 µM containing DMEM cell media.  We observed strong 
blue fluorescence in live cells using excitation and absorbance filters 360/40 and 470/40 
nm, respectively (Figure 39) which was similar to the fluorescence that Ito et al., 
observed during the reaction of  azido modified cAMP and a difluorinated cyclooctyne in 
HeLa cells.124 In our negative controls, background fluorescence was indistinguishable in 
cells incubated without azide 214 or cyclooctyne 217. To distinguish between 
intracellular and extracellular fluorescent click reactions, cells were also treated with 
trypan blue to determine the presence or absence of extracellular fluorescence via a 
quenching mechanism.266 Trypan blue cannot diffuse through the cell membrane of 
viable cells and hence can only quench fluorescence that occurs outside of the cell. Cells 
undergoing the click reaction and co-treated with trypan blue did not show any difference 
in fluorescent intensity compared to control (data not shown) and indicated that there was 
no extracellular triazole product fluorescence.  Hence, we concluded that fluorescence 
was intracellular and not the result of the click reaction occurring on the surface of the 
cell membrane. As shown in Figure 42, the 1 µM dose of compounds 214 and 217 
showed a strong fluorescent localization to the nucleus. Similarly, in Figures 43 and 44, 
the 1 µM dose of compounds 201 and 223 or 202 and 217 also showed a moderate 
fluorescent localized in the nucleus. Because MCF-7 cancer cells are undergoing rapid 
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scope of my dissertation, the long-term implications of this in situ click chemistry drug 
delivery strategy embodied in click substrates 201, 202 and 214 could allow for a more 
precise monitoring of dosage levels, as well as an improved understanding of cellular 
uptake and release mechanisms that could ultimately be translated to a more efficient 
treatment of diseases such as cancer. 
3.2.4 Fluorescence Lifetime Imaging Microscopy  
In order to determine fluorescence lifetime within living cells, frequency-domain 
fluorescence lifetime imaging microscopy (FD-FLIM) was conducted on MCF-7 cells 
incubated with the triazole products 219, 235 or 244, Figure 46. The FD-FLIM is an 
imaging technique capable of image acquisition rates that are compatible with in vivo 
imaging, while also offering a means to visualize the individual lifetime components of a 
sample (i.e. the polar plot histogram).267 The technique allows one to compare the 
lifetime characteristics, τ value, of compounds in vitro and in vivo.  
After incubation of MCF-7 cells with triazoles 219, 235 or 244, the fluorescent 
signal from cell nuclei were isolated for lifetime measurement and the average lifetime 
from multiple cells were calculated for each compound, Table 7. The lifetime value 
obtained for arabino triazole adduct 219 was much higher in vivo (2.66 ns) than that 
found in vitro (1.60 ns; Table 2). The discrepancy in lifetimes suggests that in a methanol 
solution 219 exists in base conformations (syn over anti, Figure 45A; as discussed 
above268,269) which populates the fast lifetime (0.6 ns); in the cell, however, when the 
compound has already been incorporated into a DNA strand and does not have the 
flexibility to rotate from the anti conformation needed for a Watson-Crick base pair to the 
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Compound Mean lifetime (ns) SD n  (# nuclei) SEM 
219 2.66 0.159 13 0.044 
219a 2.61 0.103 11 0.031 
234 2.66 0.102 16 0.026 
244 2.73 0.093 14 0.025 
       aTriazole adduct 219 synthesized by in vivo click reaction  
Table 7. Mean lifetime of nucleoside triazole adducts within MCF-7 cells determined by Frequency-Domain Lifetime 
Imaging (FD-FLIM). 
Intensity Lifetime Polar Plot 
219a 
234 
244 
   
Figure 47. Representative images of fluorescence intensity (left), fluorescence lifetime (middle), and Polar 
Plot histogram (right) for triazole adducts 219, 235 or 244 (1 µM) in MCF-7 cells. 
Fluorescence intensity images display an intensity range from 1.0 (background intensity) to 2.0+ (2x 
background and greater). Fluorescence lifetime heat maps display lifetimes ranging from 2.0 ns (and 
below) in blue to 3.0 ns (and above) in red. Polar plot histograms depict the x,y coordinates [Mcos(ΦF), 
Msin(ΦF)] of pixels within nuclei (outlined in the corresponding lifetime image). Experimental component 
lifetimes are indicated on the semi-circle (green circles), as well as the group mean lifetime for the specific 
compound. a Images for 219 are for the triazole adduct synthesized using an in vivo click reaction. 
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3.3 Phosphorylation of Azido Modified Nucleosides 
Nucleoside triphosphates (NTPs and dNTPs) are the building blocks of nucleic 
acids and are involved in many important processes including neurotransmission, DNA 
replications, metabolism and polysaccharide biosynthesis.273 Typically NTPs and dNTPs 
are synthesized via one of two ways: chemically or enzymatically; however, no single 
chemical or enzymatic method has been reported thus far that can extend to all natural 
and unnatural nucleosides. Because of the presence of several reactive moieties (i.e., 
hydroxyl and amino groups) selective 5' phosphorylation often requires a 
protection/deprotection sequence and tedious purification to remove undesired 
byproducts or regioisomers.273  
3.3.1 Survey of Chemical 5'-Phosphorylation of Nucleosides 
Nucleotides were originally synthesized using phosphorochloridates which 
involved a complicated reaction sequence, fairly low selectivity and yields.274-275 In 1967, 
Yoshikawa and coworkers were the first to directly use phosphoryl chloride for a 
nucleoside phosphorylation, Scheme 49.276 They found that using a trialkylphosphate as 
the solvent accelerated the rate of the reaction of nucleosides with phosphoryl chloride at 
the 5' position of unprotected nucleosides. Thus, they were able to phosphorylate 
adenosine 249 with phosphoryl chloride and either triethyl or trimethyl phosphate to give 
250 which was further phosphorylated with pyrophosphate to afford 251.  
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Scheme 49. Yoshikawa 5'- Phosphorylation Method 
  In 1984, Poulter and coworkers277-278 described a protocol for the synthesis of 
nucleotide 5'-diphosphates (e.g., 253), Scheme 50. Their strategy involved the 
nucleophilic displacement of 5'-O-tosyl nucleosides 252 by the tris(tetra-n-
butylammonium) form of pyrophosphoric acid at ambient temperature. They also 
describe the synthesis of ATP using tetrakis(tetra-n-butylammonium) triphosphate.    
 
Scheme 50. Poulter Phosphorylation Method 
Later, Ludwig and Eckstein279 developed a procedure for the synthesis of 
nucleotide 5'-triphosphates using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one 255, 
Scheme 51. Thus, 255 phosphitylates the 5'-hydroxyl of a protected adenosine 254 to 
form intermediate 256, which on subsequent reaction with pyrophosphate produces, in a 
double displacement, cyclic phosphite 257. Oxidation with iodine and water gives 5'-
triphosphate 251.  
86 
 
 
Scheme 51. Eckstein 5'-Phosphorylation Method 
3.3.2 Attempted Azidation of 2'-Deoxyadenosine-5'-triphosphate 
Initially, we envisioned the installation of the azido group on the pre-made 
nucleotide through the insertion of a bromine atom at the C8 position and then a 
substitution with an azido group following a modified version of the procedure by 
Meffert et al., Scheme 52.280  Treatment of dATP 258 with bromine in potassium acetate 
followed by ion exchange purification with DEAE-Sephadex and lyophilization gave 8-
bromo-dATP 259. Thus, 8-bromo analogue 259 was reacted with sodium azide, instead 
of the prescribed hydrazoic acid281-283 because hydrazoic acid is very toxic, explosive and 
not commercially available. Unfortunately however, I was never able to obtain azide 260 
and only recovered what seemed to be intact 8-bromo starting material 259.   
 
Scheme 52. Attempted Synthesis of 8-azido-dATP by Azidation of dATP 
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3.3.3 Attempted Phosphorylation of 8-azido-2'-deoxyadenosine 
Next, I shifted my strategy from modifying the premade nucleotide (i.e. 258) to 
phosphorylation of the azido nucleoside (i.e. 261), Scheme 53. Thus, I employed the 
typical Yoshikawa procedure276 in which the unprotected nucleoside 261 is treated with 
phosphoryl chloride in the presence of a trialkyl phosphate at 0 °C. Unfortunately, this 
method failed to show more than 5-10% conversion to the lower moving 5'-
monophosphate 262 by TLC even after allowing the reaction to stir at ambient 
temperature overnight. Nevertheless, addition of 2 molar equivalents of pyrophosphate to 
this reaction mixture also failed to give the corresponding trinucleotide 260.  The TLC 
analysis of this reaction showed no significant change and mostly unreacted 261.  
 
Scheme 53. Attempted Synthesis of 8-azido-dATP using the Yoshikawa procedure 
Next, I tried phosphorylation using the Eckstein procedure, Scheme 54.275 The 8-
azido-2'-deoxyadenosine 261 was dissolved in a mixture of pyridine and dioxane in the 
presence of 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one 262 which should have 
yielded activated phosphite 263; however, tracking the reaction by TLC showed that only 
traces of a more polar lower moving spot were formed. This new lower moving spot 
could have been the amino product of the reaction between the trivalent phosphorous of 
262 and the azido group in a Staudinger reduction.284-285  
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Scheme 54. Attempted Synthesis of 8-azido-dATP using the Eckstein procedure 
 The Poulter method277-278 for phosphorylation was then attempted to synthesize 
nucleotide diphosphate 266, Scheme 55. Tosylation of the azido stating material 261 
proved to be troublesome and only provided 5'-tosyl analogue B8 in very low yields. 
Nevertheless, treatment of activated analogue 265 with pyrophosphate in acetonitrile for 
72 h failed to give the corresponding diphosphate analogue 266 and also resulted in the 
recovery of tosylated precursor 265.  
 
Scheme 55. Attempted Synthesis of 8-azido-dATP using the Poulter Procedure 
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3.3.4 Survey of Enzymatic 5'-Phosphorylation of Nucleosides  
Enzymatic conversion of nucleosides and deoxynucleosides to their 
corresponding mono-, di- and triphosphate analogues requires the use of several kinases 
but is typically an effective method for synthesizing nucleotides.286-287 Traditionally, 
kinases used for phosphorylation are typically specific for their natural substrates; 
however, there has been substantial work done on kinase mediated phosphorylation of 
modified nucleosides including nucleosides with azide modifications.288 
 Human deoxycytidine kinase (HdcK)287, 289 is an enzyme that has been intensely 
studied for phosphorylation; it was found that deoxycytidine (dC), deoxyguanosine (dG) 
and deoxyadenosine (dA) are suitable substrates. Thus, HdcK has broad substrate 
specificity, and does not display selectivity on the basis of the chirality of the substrate. 
Cytidine (Uridine) monophosphate Kinase (CMP-UMPK)290 is the enzyme that is most 
commonly used for the synthesis of diphosphates nucleotides. It normally catalyzes the 
phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. As my 
azido nucleosides have an adenine base, the CMP-UMP kinase would not work, requiring 
another kinase. For adenine containing nucleosides, myokinase has been utilized in the 
past to obtain the corresponding diphosphate nucleotide.291 For the synthesis of 
nucleoside triphosphates from diphosphates, pyruvate kinase (PK) is most commonly 
utilized.292 It is typically robust, very flexible and not highly specific to substrates while 
using phosphoenolpyruvate as its phosphate source. 
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Foetus. Trichomonas vaginalis is a protozoal parasite that causes trichomoniasis, a 
common sexually transmitted disease in humans. The current FDA-approved treatments 
for this disease are 5-nitroimidazoles derivatives: metronidazole, also known as Flagyl, 
and tinidazole, which is also known as Tindamax. However, approximately 5% of all 
reported cases show some level of resistance to metronidazole.226 
3.4.1 Screening of Compounds 
In order to select the most promising candidate we screened a library of various 
purine 267–291, Figure 48, and pyrimidine 292–299, Figure 49, nucleoside analogues 
modified at C2', C3' or C5' of the ribose ring and at position C2 of adenine ring against T. 
vaginalis232 in vitro. The most potent compounds were found to be 2'-modified adenosine 
derivatives, especially the analogues having an arabino configuration. Thus, we found 
that 9-(2-deoxy-2-fluoro-β,D-arabino-furanosyl)adenine (arabino-F-Ado) 272 is more 
potent against T. vaginalis than the FDA approved treatment, metronidazole. It inhibited 
the growth of T. vaginalis with an IC50 of 0.09 μM, whereas metronidazole inhibits 
growth of parasite with an IC50 of 0.72 μM, Table 8. Moreover, 272 is also active against 
the metronidazole resistant strain T. vaginalis with an IC50 value of 0.21 μM. Encouraged 
by these exciting results we decided it would be important to visualize the cellular 
localization and potential cellular targets of F-arabinoadenosine 272. 
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Figure 48. Modified adenosine analogues tested against T. vaginalis. 
 
Figure 49. Modified uridine analogues tested against T. vaginalis 
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Compound IC50 Value (µM) 
Metronidazole 0.72 
269 2.94 
271 3.60 
272 0.09 
273 5.93 
276 1.61 
284 48.5 
287 53.3 
289 29.5 
Table 8. Calculated IC50 values of the most potent compounds determined for T. vaginalis strain T1 and compared with 
metronidazole 
3.4.2 Design of Tagging Experiments 
Initially, I envisioned tagging at the 3' and 5' hydroxyl groups; however, the  
strategy was not advantageous because 3' and 5' hydroxyl phosphorylation might be an 
important step in the mechanism of action. Also, our attempts on coupling a carboxylic 
acid to incorporate a tag at the exocyclic amine (e.g., 300) were unsuccessful with fluoro-
arabinoadeosine, Figure 50.  
 
Figure 50. Tagging of Exocyclic Amine of F-arabinoadenosine 272 
I then came across a publication detailing a procedure for visualizing the 
subcellular localization of K11777,247 a protease inhibitor of T. brucei, a parasite similar 
to T. vaginalis. To visualize the location of K11777, live parasites were directly treated 
with an alkyne modified analogue of K11777, fixed, and reacted in situ with a fluorescent 
azide reporter, then imaged.  I, therefore, developed our new experiment design, on a 
modified version of the proteomic profiling of K11777, in which live T. vaginalis 
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parasites are directly treated with azide modified fluoro-arabino analgoue, fixed, tagged, 
and then imaged.  
3.4.3 Synthesis of Azide Modified Substrates 
To accomplish this goal, I selected 8-azido-2'-fluoro-arabinoadenosine as our 
imaging probe because modifications at the C8 position remain in the major groove and 
do not affect the formation of DNA duplex.248  Thus, I synthesized 8-bromo analogue 300 
by direct bromination250 of parent compound F-ara-Ado 272. Further treatment of 8-
bromo derivative 300 with sodium azide afforded azido modified clickable analogue 215, 
Scheme 57. The identities of both novel compounds 215 and 300 were confirmed with 
UV-Vis, NMR and HRMS. The 8-bromo analogue 300 and 8-azido analogue 215 were 
also tested for in vivo inhibitory activity and showed 15.5 ± 0.9 and 19.6 ± 8.1 % 
inhibition at 100 µM, respectively.  
 
Scheme 57. Synthesis of 8-azido-fluoro-arabinoadenosine 215 
3.4.4  Model Studies  
I performed several model studies of the click reaction between azide 215 and 
commercially available cyclooctyne 218 that is conjugated via a linker to biotin before 
attempting the in situ labeling reaction, Scheme 58. Hence, the click reaction of 215 with 
unmodified cyclooctyne OCT 217 afforded derivative 221; the identity of this compound 
was confirmed by NMR and LC-MS analysis. The labeling reaction with cyclooctyne 
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218 which is conjugated to biotin was successful albeit much messier on 1H NMR 
showed a new peak on HPLC, corresponding to the labeled compound, 301.  
 
Scheme 58. Model click reactions on 8-azido-fluoro-arabinoadenosine 215 
We intended to apply this new methodology for cellular localization and 
identification of potential cellular targets in collaboration with Dr. Kirkwood Land and 
Dr. Lisa Wrischnik at the University of the Pacific. This work is currently underway and 
may provide a basis for development of new drugs against this important human parasite 
3.5 Synthesis of Azido-Modified α-Ketoglutarate 
Next, we decided to take advantage of the click chemistry for subcellular 
localization that I developed previously; I decided to explore the application of this new 
methodology to identify the cellular targets of active compounds against the ubiquitous 
bacteria Pseudomonas aeruginosa in collaboration with Dr. Kalai Mathee from Florida 
International University's Department of Human and Molecular Genetics.  
3.5.1 General Information about Pseudomonas aeruginosa  
Pseudomonas aeruginosa is a gram negative, rod-shaped, asporogenous, and 
monoflagellated bacterium.293 It uses aerobic respiration for metabolism but can respire 
anaerobically on nitrate or other electron acceptors. P. aeruginosa can catabolize a large 
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variety of organic molecules as carbon sources making it a pervasive microorganism 
usually found in soil, water, plants, sewage, and even immunocompromised humans.294  
 Analysis of P. aeruginosa shows the presence of a two component system (TCS), 
MifSR (MifS-Sensor and MifR-Response Regulator), which are upstream from the 
poxAB operon. It is has been postulated that the MifSR TCS is involved in β-lactam 
resistance (i.e. antipseudomonal penicillins) by the regulation of poxB.295 In our study, te 
Mathee lab constructed mifR, mifS and mifSR deletion mutants, and compared to them to 
the wild type parent strain PAOl for differences in growth and phenotype.  
3.5.2 General information about α-Ketoglutarate 
  
Figure 51. α-ketoglutarate 
The α-ketoglutarate (α-KG) 302, Figure 51, a member of the citric acid cycle, has 
been recognized as an intermediate for both carbon and nitrogen metabolism.296 
Campbell and Stokes noted that P. aeruginosa grown in acetate rich media displayed a 
significant lag when transferred into α-KG medium suggesting the possibility of an 
inducible α-KG transporter.297  We found no P. aeruginosa growth, when the mifR, mifS, 
and mifSR deletion mutants were incubated with α-KG, indicating that either the α-KG 
was unable to cross the bacterial cell membrane because there is no transport protein or 
once the α-KG was inside the cell it was not metabolized and therefore could not be used 
as a carbon source. Interestingly, all the other components of the TCA cycle including 
citrate and isocitrate can be metabolized by the mifR, mifS and mifSR deletion mutants.  
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3.5.3 General information about 2,2-Difluoropentanedioic Acid 
 
Figure 52. 2,2-Difluoropentanedioic acid 
The 2,2-Difluoropentanedioic Acid (DFPA) 303, Figure 52, a non-metabolizeable 
fluorinated derivative of α-KG, has been used to demonstrate the signaling functions of 
α-KG in vivo. Its cellular uptake and accumulation has studied by 19F NMR.298  
3.5.4 Synthesis of Azido-Modified α-Ketoglutarate  
 
Scheme 59. Diazotization of α-ketoglutarate 
The azido-modified α-glutarate 305 was prepared using a modified procedure 
described by Lundduist and Pelletier299 for the synthesis of α-azide protected amino 
acids. First, the triflyl azide reagent was prepared from triflyl anhydride in a method 
similar to the one described previously by Wong.300 Next, the unprotected glutamic acid 
304 was combined with K2CO3 and CuIISO4 pentahydrate in distilled water and MeOH. 
The freshly prepared triflyl azide was added and allowed to stir at ambient temperature 
and pressure overnight in a Morton flask. This reaction is a biphasic reaction with two 
liquid (aqueous and organic) phases; therefore, a Morton flask with a small magnetic 
stirrer must be used to maximize the turbulence and shear of the mixture. In the morning, 
the organic solvents were removed in vacuo, the aqueous slurry was diluted with H2O 
and acidified to pH 6 with conc. HCl.  
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The product can be extracted using two different methods: A) Buffered 
Extraction: Phosphate buffer (0.25 M pH 6.2) was added and extracted with EtOAc to 
remove the sulfonamide byproduct. The aqueous phase was once again acidified to pH 2 
and the extracted with EtOAc. B) Acidification Extraction: The aqueous layer was 
washed (4x) with EtOAc to remove the sulfonamide byproduct. The aqueous phase was 
once again acidified to pH 2 and the extracted with EtOAc. These extracts were pooled 
together, dried with MgSO4 and evaporated to dryness to give 305 as a pale oil which 
was used directly in a click reaction. Although, the buffered extraction method gave pure 
305, the yields were low when compared to the method requiring acidification only.  
3.5.5 Proposed testing on Pseudomonas aeruginosa 
We proposed using SPAAC to study the inhibitory concentration and localization 
of azido modified glutaric acid 305 in vivo in P. aeruginosa. Growth curves for cells that 
have been infected with P. aeruginosa and treated with 305 were constructed to test if 
305 can be utilized as an alternative carbon source and what is its minimum inhibitory 
concentration. We postulated that it should be similar to that of α-KG 304. Second, we 
envisioned a tagging study which will utilize my previously developed SPAAC method 
and a fluorogenic cyclooctyne to prove that azido-KG 305 is not getting across the inner 
membrane of the cell when pcaT has been knocked down and is not present, Figure 53A. 
Thus, we should only see fluorescence outside of the cell or between the outer and inner 
membrane. This experiment will also be done with cells that that express pcaT to prove 
that it is a transporter of α-KG and only then should we see fluorescence inside of the cell 
and not in the cell membrane, Figure 53B. Lastly, an antibiotic resistance assay will be 
99 
 
performed to determine if the azido derivatized α-KG 305 has antibacterial properties and 
if it works synergistically with other known antibiotics.  
 
Figure 53. α-KG tagging study 
3.5.6 Model Click Reactions with Azido-Modified α-Ketoglutarate  
 
Scheme 60. Model SPAAC of α-azidoketoglutarate and OCT 
The α-ketoglutarate modified with azido group at the C2 position 305 undergoes 
SPAAC reaction efficiently in vitro, Scheme 60. Thus, equivalent amounts of 305 reacts 
with OCT 217 in aqueous media at ambient temperature for 6 h to give 306 in a high 
yield (82%). This work is currently ongoing in the Mathee laboratory.  
3.6  Synthesis of SAM Analogues for Probing TRMD 
3.6.1 General Information about TRMD Enzyme 
The tRNA(m1G37)methyltransferase (TrmD) enzyme catalyzes the transfer of a 
methyl group from SAM to guanosine at position 37 within a division of bacterial tRNA. 
This function is essential in preventing frameshift errors thereby maintaining the correct 
reading frame during translation.301-302 TrmD is made up of two separate domains, a 
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larger NTD domain and a smaller CTD domain connected by an extended flexible linker, 
Figure 54.301, 303 The flexible linker appears to play a central role as the possible lid to 
cover the active site upon binding the cognate tRNA.301 
 
Figure 54. tRNA(m1G37)methyltransferase (TrmD) Enzyme 
The adenine portion of SAM is bound in one part of the trefoil binding pocket, 
and the amino acid portion is buried in another portion of the pocket with the positively 
charged methyl group jutting out of the binding pocket. A total of nine H-bonds suspend 
SAM in the TrmD binding pocket.301 Typically, the O4’-C4’-C5’-SR  dihedral angle in 
most SAM dependent methyltransferase is -170° to -180° and 160° to 180° which places 
the amino acid moiety in an extended conformation, Figure 55A.304 However, when SAM 
is bound in the TrmD binding pocket it adopts a novel, bent conformation with its O4’-
C4’-C5’-SD dihedral angle -62°, Figure 55B.301  
                       
 
 
 
 
Figure 55. A. Typically conformation of SAM in methyltransferase enzyme active site. B. Conformation of SAM in 
the TrmD active site. 
A.             B.  
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3.6.2 Synthesis and Tagging of EnYn Analogue of SAM 
Methyltransferases (MTases) catalyze highly specific transfers of methyl groups from 
the ubiquitous cofactor S-adenosyl-L-methionine to various nucleophilic positions in 
biopolymers like DNA, RNA, and proteins. Doubly activated SAM analogue 20 was 
synthesized for use in reactions with methyltansferases, enzymatic tagging and click 
chemistry for eventual introduction of a fluorophore.305-306  
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Scheme 61. Synthesis of AdoEnYn and application with Trm1 
Doubly activated AdoEnYn 310 was synthesized using the procedure by 
published Weinhold and coworkers, which reacted SAH 307 with mesyl activated (E)-
pent-2-en-4-yn-1-ol 309, Scheme 61.307 Thus, treatment of freshly distilled (E)-pent-2-en-
4-yn-1-ol 308 with 1.1 equivalents of mesyl chloride gave mesyl activated analogue 309. 
The activated alcohol 309 was dissolved in a mixture of formic and acetic acid (1:1) and 
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added directly to SAH 307. After 14 h, the reaction was quenched by the addition of 
water and purified with RP-HPLC to give 310.  
Initial reactions with enzyme Trm1 showed that AdoEnYn 310 can inhibit 
AdoMet-dependent methylation of tRNA, indicating that there is competition with the 
authentic methyl donor. An inhibition analysis revealed that AdoEnYn has a similar 
affinity to the methylation enzyme in the range of Kd of 11-17 µM. Furthermore, 
AdoMet-methylated tRNA synthesized in the presence of AdoEnYn has reduced physical 
blockage to reverse transcriptase at the expected site on the tRNA, indicating that there is 
inhibition of methylation to the expected site. This suggests that AdoEnYn can be 
incorporated into tRNA in place of AdoMet. LC-MS/MS analysis of a reaction between 
tRNA, Trm1 and AdoEnYn showed EnYn2G 311 as well as expected fragmentation 
(e.g., 312) indicating that the EnYn group was transferred from AdoEnYn 310 by 
methyltransferase Trm1 to guanosine on tRNA 21. 
3.6.3 Design and Attempts at Synthesis of Cyclic Analogues 
The research aim of this section was the synthesis of constrained S-adenosyl-L-
methionine analogues which will mimic the naturally occurring bent conformation of 
SAM in the tRNA(m1G37)methyltransferase (TrmD) binding pocket, Figure 53. These 
analogues will serve as probes to study the transfer of the protruding methyl group and 
possibly as tRNA inhibitors. To achieve this goal I designed bicyclic nucleoside 
derivatives having 9, 10, or 11 membered rings bridging from the C5’ thioether to either 
the 3’ OH or 2’ OH groups which will mimic the naturally occurring bent conformation 
of SAM in the TrmD binding pocket. Numerous synthetic pathways including 
lactonization, lactamization and ring closure metathesis (RCM) were explored in attempts 
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at the synthesis of novel constrained SAM analogues. Preliminary docking studies of 
lactone derivatives, conducted in the laboratory of Dr. Ya Ming Hou at Thomas Jefferson 
University, suggested that derivatives with either xylo or arabino  conformations are 
better accommodated by the TrmD binding pocket.  
3.6.3.1 Lactonization 
In this approach, I targeted the synthesis of macrolactone 316 that featured an 
ester linkage to the 3'-OH and a thioether linkage to the 5'-S forming a 9 membered ring, 
Scheme 62. Thus, 314 was prepared via a substitution reaction of 5’analogue 313 with 
the open form of γ-butyrothiolactone. Deprotection of methyl ester 314 with NaOMe 
gave acid 315. Macrocyclization of thioether 315 was attempted using an HOBt coupling 
protocol;308 however, my attempts at this procedure were unsuccessful. This could be 
attributed to the instability of the resulting ester; because an ester linkage is prone to 
hydrolysis and therefore too unstable to use as my key linkage. 
 
Scheme 62. Synthesis and attempted cyclization of model SAM analogue 315 
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3.6.3.2 Lactamization 
I subsequently turned my attention to the synthesis of macrolactam 317, Figure 
56, an analogue of aminonucleoside antibiotic, Puromycin 318, which is an analogue of 
the 3’ end of a tyrosyl-tRNA since it is comprised of a molecule of adenosine, linked at 
the 3’ position to a molecule of tyrosine via a stable non-hydrolysable amide bond. For 
this reason, I designed macrolactam 317 which is an analogue of both S-Adenosyl-l-
Homocysteine and Puromycin since it combines a molecule of adenosine and one of 
homocysteine linked via a non-hydrolysable amide linkage at the 3' position.  
 
Figure 56. SAH macolactam and Puromycin 
Lactam 317 can be synthesized from key intermediate azide 320 which I 
synthesized in 7 steps from adenosine, Scheme 63.309-310 
 
Scheme 63. Overview of the synthetic pathway for the synthesis of macrolactam 317 
The synthesis of lactam 317 was attempted several different ways, Scheme 64. 
Substitution of the 5’ chloro- group of 320 with the sodium salt of homocysteine afforded 
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derivative 321 in a fair yield. In an attempt to optimize this yield the reaction was 
repeated with homocysteine lactone and by in situ reduction of N-Boc protected 
homocystine with Dithiothreitol (DTT); only the latter strategy yielded the corresponding 
Boc-protected analogue 323 in low yields. This method was later abandoned because of 
the very low yields of each of the synthetic manipulations.  
 
Scheme 64. Homocysteine substitution of 5'-chloroadenosine analogue 321 
Cyclization was then attempted in the opposite way, Scheme 65. Azide 320 was 
condensed with the oxybenzotriazolyl ester of N-Boc-S-Trityl-Homocysteine, which was 
formed in situ by the treatment of commercial N-Boc-S-Tr-Hcy with HOBt and DIC at 0 
°C,311 to afford amide 324. The tert-Butyloxycarbonyl (Boc) protection on the amino 
group was easily deprotected using a mixture of trifluoroacetic acid and dichloromethane 
106 
 
at ambient temperature;312 however, deprotection of the S-trityl group was unsuccessful 
and led to significant glycosidic bond cleavage. Furthermore, staining of a TLC of the 
reaction mixture with Ellman's reagent, a stain used to visualize free thiol groups, showed 
no yellow color, thus proving that no free thiol was present. Several attempts at this 
reaction all showed similar results, glycosidic cleavage and no free thiol. Thus, this 
method was also abandoned.  
 
Scheme 65. Synthesis of amide linked homosysteine-adenosine conjugate 324 
3.6.3.3 Ring Closure Metathesis  
Ring closure metathesis (RCM) has been used to the past to synthesize previously 
difficult to assemble rings. RCM is an alkene synthesis which uses a Grubbs’ catalyst, 
yielding the cycloalkene and a volatile alkene. Thus, allylation of 5’-chloro analogue 313 
with dibutyltin oxide and allyl bromide yielded a mixture of 2’ and 3’ O-allyl isomers 
327 and 326, respectively, which were chromatographically separated to yield pure 3’ O-
allyl derivative 326, Scheme 66.313-315 Unfortunately, only trace amounts of pure 326 
were recovered indicating that 327 was the major allyl compound formed because the 2' 
hydroxyl is more reactive since it is adjacent to the glycosidic bond and electron 
withdrawing base. Treatment of 327 with allyl mercaptan should lead to the di-allyl 
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compound; however, NMR analysis of the product showed that the 5'-allyl group had 
isomerized to a vinyl moiety affording 330 instead.316  Treatment of 313 with allyl 
mercaptan gave 328 in very low yields. Also, subjection of di-allyl derivative 329 to a 
RCM reaction using the second-generation Grubbs’ catalyst317 should yield the 
unsaturated bicyclic derivative as expected on the basis of literature precedence for the 
synthesis of other bicyclic nucleoside analogues. This approach, however, was never 
attempted because of the low preparative yields of key di-allyl starting material 329 most 
probably as a result of isomerization of the 5' S-allyl group.  
 
Scheme 66. Synthesis of 3',5' diallylated adenosine 329 
4 Experimental 
4.1  General Procedure 
Materials and General Methods. Detailed methods and characterization can be 
found in the Supporting Information. The 1H (400 MHz), 19F NMR (376.4 MHz) and 13C 
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(100.6 MHz) were recorded at ambient temperature in solutions of ACN-d3, D2O, or 
DMSO-d6, as noted. The reactions were followed by TLC with Merck Kieselgel 60-F254 
sheets, and products were detected with a 254nm light. Column chromatography was 
performed using Merck Kieselgel 60 (230−400 mesh). Reagent-grade chemicals were 
used, and solvents were dried by reflux distillation over CaH2 under nitrogen gas unless 
otherwise specified. Azido nucleoside substrates were prepared as described in literature 
(200,249 214,318 216,319 and 243255) or in experimental section (215), or are commercially 
available (201, 202 and 229) from Carbosynth. Cyclooctynes 217, 218, 223 and 227 are 
commercially available from Kerafast, SynAffix, Sigma Aldrich or Berry & Associates. 
Lipofectamine LTX and Plus reagent was purchased from Invitrogen. HPLC analysis was 
performed on a semi-preparative Phenomenex Gemini RP-C18 column (5 μ, 25 cm × 1 
cm) with UV detection at 254 nm. 
4.2 Synthesis of Novel Azido Nucleosides 
8-Bromo-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (212). 1,3-
Dibromo-5,5-dimethylhydantoin (DBH; 29.1 mg, 0.10 mmol) was added to a stirred 
solution of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenineS320 (208 41 mg, 0.15 
mmol) in DMF (1.5 mL). The resulting pale-yellow solution was stirred at ambient 
temperature for 5 h. Volatiles were evaporated in vacuo and the resulting residue was 
purified on silica gel column chromatography (EtOAc → 4% MeOH/EtOAc) to give  212 
(27.8 mg, 54%) as a white solid: UV λmax 262 nm (ε 15 400); 1H NMR (DMSO-d6) δ 
3.73-3.80 (m, 2H, H5' & 5"), 3.82-3.86 (m, 1H, H4'), 4.76 (ddd, J = 22.3 Hz, 7.7 Hz, 5.7 
Hz, 1H, H3'), 5.33 (dt, J = 54.3 Hz, 5.7 Hz, 1H, H2'), 6.47 (dd, J = 8.3 Hz, 6.5 Hz, 1H, 
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H1'), 8.10 (s, 1H, H2); 19F NMR (DMSO-d6) δ -197.94 (ddd, J = 53.7, 21.3, 8.4 Hz); 13C 
NMR δ 60.58 (C5'), 72.66 (d, J = 22.2 Hz, C3'), 81.75 (d, J =8.9 Hz, C4'), 83.32 (d, J = 
17.4 Hz, C1'), 96.07 (d, J = 195.6, C2'), 118.98 (C5), 125.76 (C8), 150.36 (C4), 152.49 
(C6), 154.52 (C2); HRMS (ESI+) m/z calcd C10H11BrFN5O3 (M+H)+: 348.0102, found: 
348.0095. 
8-Azido-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (215). NaN3 (18.0 
mg, 0.30 mmol) was added to a stirred solution of 212 (20 mg, 0.06 mmol) in DMF (2.0 
mL). The resulting pale-yellow solution was stirred at 70 °C overnight.  After 16 h, the 
volatiles were evaporated in vacuo and the resulting residue was purified on column 
chromatography (EtOAc → 4% MeOH/EtOAc) to give 215 (10.3 mg, 61%) as a white 
solid: UV λmax 280 nm (ε 14 500); 1H NMR (DMSO-d6) δ 3.70-3.78 (m, 3H, H5', H5" & 
OH), 4.74-4.82 (m, 1H, H4'), 5.10 (t, J = 6.3 Hz, 1H, H3'), 5.31 (dt, J = 54.5 Hz, 6.1 Hz, 
1H, H2'), 5.90 (d, J = 4.7 Hz, 1H, OH), 6.29 (t, J = 6.96, 1H, H1'), 7.29 (bs, 2H, NH2), 
8.09 (s, 1H, H2); 19F NMR (DMSO-d6) δ -199.06 (ddd, J = 53.9, 21.7, 7.1 Hz, 1F); 13C 
NMR δ 60.99 (C5'), 72.56 (d, J = 21.7 Hz, C3'), 80.22 (d, J = 17.5 Hz, C1'), 81.82 (d, J 
= 9.4 Hz, C4'), 96.08 (d, J = 195.4 Hz, C2'), 116.61 (C5), 143.93 (C8), 149.70 (C4), 
151.76 (C6), 154.29 (C2); HRMS (ESI+) m/z calcd C10H11FN8NaO3 (M+Na)+: 333.0830, 
found: 333.0825. 
4.3  Synthesis Of Nucleoside Click Adducts 
8-(1,2,3-Triazol-1H-yl)adenosine-OCT adduct (203). Typical Procedure. 
Cyclooctyne 217 (endo; 7.6 mg, 0.05 mmol) was added to a stirred solution of 8-
azidoadenosine249 200 (15.0 mg, 0.05 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at 
ambient temperature. After 3 h, the volatiles were evaporated in vacuo and the resulting 
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residue was purified on silica gel column chromatography (EtOAc → 20% 
MeOH/EtOAc) to give 7 as mixture of regioisomers (1:1; 21.0 mg, 96%) as a white solid. 
Alternatively the crude reaction mixture was passed through a 0.2 μm PTFE syringe 
filter, and then purified on the semipreparative HPLC column (17% ACN/H2O, 2.0 
mL/min) to give 203 (1:1; 21.0 mg, 96%) as a white solid (tR = 4.5–8.2 min): UV λmax 
270 nm (ε 21 100), λmin 241 nm (ε 12 100); 1H NMR (DMSO-d6) δ 0.84-0.95 (m, 2H, 
Hγ), 0.99 ("q", J = 9.4 Hz, 0.5H, CH cyclopropyl), 1.00 (q, J = 9.4 Hz, 0.5H, CH 
cyclopropyl), 1.51-1.74 (m, 2H, Hβ),  2.00-2.19 (m, 2H, Hβ), 2.57-2.67 (m, 1H, Hα), 
2.77-2.87 (m, 1H, Hα), 2.87-2.99 (m, 1H, Hα), 3.09-3.15 (m, 1H, Hα), 3.42-3.53 (m, 3H, 
CH2 & H5'), 3.58 ("dd" J = 12.2, 4.2 Hz, 1H, H5"), 3.85-3.93 (m, 1H, H4'), 4.00-4.07 (m, 
1H, H3'), 4.35 (t, J = 4.9 Hz, 1H, OH), 4.93 ("q", J = 5.2 Hz, 0.5H, H2'), 5.00 ("q", J = 
5.2 Hz, 0.5H, H2'), 5.12-5.23 (m, 2H, H1' & OH), 5.36-5.52 (m, 2H, 2 x OH), 7.78 (br s, 
2H, NH2), 8.23 (s, 1H, H2); 13C NMR (CD3CN) δ 18.44, 18.58, 18.62, 20.14, 20.22, 
20.82, 20.88, 21.21, 21.30, 22.33, 22.44, 25.04, 58.02, 58.81, 62.08, 69.18, 70.83, 71.01, 
72.39, 72.44, 72.56, 86.96, 87.05, 89.39, 90.92, 138.39, 138.42, 138.47, 144.87, 144.93, 
148.52, 152.01, 153.35, 156.31; HRMS (ESI+) m/z calcd C20H27N9O5 (M+H)+: 459.2054, 
found: 459.2050 
Note: Analogous treatment of 200 (7.0 mg, 0.023 mmol) with 217 (4.7:1, exo-
endo; 3.4 mg, 0.023 mmol) also gave 203 (~1:1; 10.0 mg, 96%).  
9-(β-D-Arabinofuranosyl)-8-(1,2,3-triazol-1H-yl)adenine-OCT adduct (219). 
Cyclooctyne 217 (4.7:1, exo-endo; 4.9 mg, 0.02 mmol) was added to a stirred solution of 
214318 (10.0 mg, 0.02 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at ambient 
temperature. After 1 h, the volatiles were evaporated in vacuo and  the resulting residue 
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was purified by column chromatography on silica gel (EtOAc → 20% MeOH/EtOAc) to 
give 219 as mixture of regioisomers (~1:1; 12.8 mg, 93%) as a white solid: UV λmax 273 
nm (ε 17 500), λmin 248 nm (ε 8700);  1H NMR (DMSO-d6) δ 0.83-0.96 (m, 2H, 2 x Hγ), 
0.96-1.07 (m, 1H, CH cyclopropyl), 1.50-1.70 (m, 2H, 2 x Hβ), 2.01-2.19 (m, 2H, 2 x 
Hβ), 2.56-2.71 (m, 1H, Hα), 2.78-2.95 (m, 2H, 2 x Hα), 3.11 ("q", J = 3.3 Hz, 0.5H, Hα), 
3.15 ("q",  J = 3.6 Hz, 0.5H, Hα), 3.46-3.53 (m, 1H, H5'), 3.58-3.66 (m, 3H, H5'' & 
CH2OH), 4.20 (q, 1H, J = 5.6 Hz, H4'), 4.26-4.37 (m, 1H, H2' & H3'), 5.08-5.15 (m, 1H, 
OH), 5.41 (br s, 1H, OH), 5.63-5.67 (m, 1H, OH), 5.69 (d, J = 6.7 Hz, 0.5H, H1'), 5.71 
(d, J = 6.8 Hz, 0.5, H1'), 7.61 (s, 2H, NH2), 8.23 (s, 1H, H2); 13C NMR (DMSO-d6) δ 
13.34, 17.42, 17.49, 19.31, 19.84, 19.87, 20.36, 20.38, 21.65, 24.12, 24.17, 30.09, 35.23, 
56.57, 59.73, 73.17, 73.28, 75.17, 75.24, 81.61, 81.69, 84.24, 84.27, 115.79, 137.15, 
137.18, 137.42, 137.43, 143.29, 143.34, 148.43, 152.46, 154.95, 162.35; HRMS (ESI+) 
m/z calcd C20H26N8NaO5 (M+Na)+: 481.1918, found: 481.1927. 
9-(β-D-Arabinofuranosyl)-8-(1,2,3-triazol-1H-yl)adenine-OCT-biotin adduct 
(220). Cyclooctyne 218 (endo; 5.5 mg, 0.01 mmol) was added to a stirred solution of 214 
(3.1 mg, 0.01 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at ambient temperature. After 
2 h (TLC showed complete conversion to the more polar product), the volatiles were 
evaporated in vacuo and the resulting residue was purified by HPLC (as described for 7) 
to give 220 (5.4 mg, 71%) as a white oil: HRMS (ESI+) m/z calcd C20H26N8NaO5 
(M+Na)+: 481.1918, found: 481.1927. 
9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-8-(1,2,3-triazol-1H-yl)adenine-
OCT adduct (221). Cyclooctyne 217 (exo:endo, 4.7:1; 3.7 mg, 0.025 mmol) was added 
to a stirred solution of 215 (7.6 mg, 0.025 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at 
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ambient temperature. After 2 h (TLC and NMR showed complete conversion of 215 to 
221) the volatiles were evaporated in vacuo to give 221 as mixture of regioisomers (~1:1; 
11 mg, 95%) as a white solid: 1H NMR (DMSO-d6) δ 0.84-0.97 (m, 2H, 2 x Hγ), 0.98-
1.07 (m, 1H, CH cyclopropyl), 1.52-1.71 (m, 2H, 2 x Hβ), 2.00-2.19 (m, 2H, 2 x Hβ), 
2.56-2.72 (m, 1H, Hα), 2.73-2.95 (m, 2H, 2 x Hα), 3.09-3.16 (m, 1H, Hα), 3.46-3.53 (m, 
2H, CH2OH), 3.54-3.67 (m, 2H, H5' & H5"), 3.69-3.75 (m, 1H, OH), 4.31-4.38 (m, 1H, 
OH), 4.63-4.77 (m, 1H, H4'), 5.06-5.12 (m, 1H, H3'), 5.23 (dt, J = 53.9, 5.7 Hz, H2'), 
5.86-5.95 (m, 2H, H1' & OH), 7.00 (br s, 2H, NH2), 8.27 (s, 0.5H, H2), 8.28 (s, 0.5H, 
H2); 19F NMR (DMSO-d6) δ -198.52 (ddd, J = 53.9, 21.4, 8.2 Hz, 0.5F), -199.01 (ddd, J 
= 53.9, 21.5, 7.3 Hz, 0.5F); HRMS (ESI+) m/z calcd C20H26FN8O4 (M+H)+: 461.2056, 
found: 461.2059. 
2'-Deoxy-8-(1,2,3-triazol-1H-yl)adenosine-OCT adduct (222). Cyclooctyne 
217 (endo; 15.7 mg, 0.1 mmol) was added to a stirred solution of 216319 (29.5 mg, 0.1 
mmol) in a mixture of ACN/H2O (3:1, 1 mL) at ambient temperature. After 3 h, the crude 
reaction mixture was passed through a 0.2 μm PTFE syringe filter, and then purified on 
the semipreparative HPLC column (17% ACN/H2O, 2.0 mL/min) to give 222 as mixture 
of regioisomers (1:1; 49.3 mg, 96%) as a white solid (tR = 13.0–16.2 min): UV λmax 272 
nm (ε 18 200), λmin 238 nm (ε 8500); 1H NMR (DMSO-d6) 0.82-0.95 (m, 2H, 2 x Hγ), 
0.96-1.07 (m, 1H, CH cyclopropyl), 1.53-1.72 (m, 2H, 2 x Hβ), 2.03-2.19 (m, 3H, H2' & 
2 x Hβ'), 2.60-2.72 (m, 2H, 2 x Hα), 2.81-2.97 (m, 2H, 2 x Hα), 3.03-3.18 (m, 3H, H2'' & 
2 x Hα), 3.37-3.45 (m, 1H, H5'), 3.47-3.59 (m, 3H, H5' & CH2OH), 3.76-3.82 (m, 1H, 
H4'), 4.30-4.37 (m, 2H, H3' & OH), 5.26 (d, J = 4.0 Hz, 1H, OH), 5.27-5.34 (m, 1H, 
OH), 5.71 (dd, J = 6.4, 3.1 Hz, 0.5H, H1'), 5.73 (dd, J = 6.4, 3.2 Hz, 0.5H, H1'), 7.72 (br 
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s, 2H, NH2), 8.26 (s, 1H, H2); HRMS (ESI+) m/z calcd C20H27N8O4 (M+H)+: 443.2150, 
found: 443.2142. 
8-(1,2,3-Triazol-1H-yl)adenosine-DBCO adduct (224). Cyclooctyne 223 (15.0 
mg, 0.055 mmol) was added to a stirred solution of 200 (16.4 mg, 0.055 mmol) in a 
mixture of ACN/H2O (3:1, 1.5 mL) at 50 °C. After 16 h, the crude reaction mixture was 
passed through a 0.2 μm PTFE syringe filter, and then injected into a semipreparative 
HPLC column (40% ACN/H2O 1.0 mL/min) to give 224 (10.6 mg, 98%) as a mixture of 
several inseparable regioisomers (tR = 15.5–23.0 min): UV λmax 276 nm (ε 16 000), λsh 
307 nm (ε 11 200), λmin 270 nm (ε 14 500). Two major isomers (~85-90% of total 
isomeric composition) had: 1H NMR (DMSO-d6) δ 1.64-1.78 (m, 2H, NH2), 2.08-2.33 
(m, 2H, CH2CO), 2.67-2.81 (m, 2H, CH2NH2), 3.31-4.18 (m, 4H, H3', H4', H5' & H5"), 
4.59 ("dm", J = 17.1 Hz, 1H, CH2), 5.08-5.18 (m, 1H, H2'), 5.19-5.55 (m, 3H, 3 x OH), 
5.72 (d, J = 7.5 Hz, 0.5H, H1'), 5.83 (d, J = 7.0 Hz, 0.5H, H1'), 5.96 (br d, J = 17.6 Hz, 
1H, CH2), 6.09 (br d, J = 17.4 Hz, 1H, CH2), 7.26-7.56 (m, 8H, Har), 8.25 (s, 0.5H, H2), 
8.28 (s, 0.5H, H2); HRMS (ESI+) m/z calcd C28H29N10O5 (M+H)+: 585.2317, found: 
585.2330. 
9-(β-D-Arabinofuranosyl)-8-(1,2,3-triazol-1H-yl)adenine-DBCO adduct 
(225). Cyclooctyne 223 (5.72 mg, 0.02 mmol) was added to a stirred solution of 201 (4.0 
mg, 0.02 mmol) in MeOH (1 mL) at 50 °C. After 16 h, the crude reaction mixture was 
passed through a 0.2 μm PTFE syringe filter, and then injected into a semipreparative 
HPLC column (Phenomenex Gemini RP-C18 column; 5 μ, 25 cm × 1 cm) (40% 
ACN/H2O, 1.5 mL/min) to give 225 (8.52 mg, 95%) as a mixture of several inseparable 
regioisomers (tR = 5.5–10.0 min): 1H NMR (DMSO-d6) δ Two major isomers (~85-90% 
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of total isomeric composition) had: 1H NMR (DMSO-d6) δ 1.42-1.78 (m, 2H, NH2), 2.01-
2.17 (m, 2H, CH2CO), 2.60-2.78 (m, 2H, CH2NH2), 3.17-3.24 (m, 2H, H4' & H5'), 3.28 
(dd, J = 11.5 Hz, 4.6 Hz, 1H, H5"), 3.83-3.87 (m, 1H, H3'), 4.10 (t, J = 6.0 Hz, 0.5H, 
H2'), 4.11 (t, J = 5.9 Hz, 0.5H, H2'), 4.49 (br s, 2H, CH2), 5.72 (d, J = 5.1 Hz, 1H, H1'), 
7.26-7.56 (m, 8H, Har), 8.09 (s, 1H, H2); HRMS (ESI+) m/z calcd C28H29N10O5 (M+H)+: 
585.2317, found: 585.2425. 
2'-Deoxy-8-(1,2,3-triazol-1H-yl)adenosine-DBCO adduct (226). Cyclooctyne 
223 (4.7 mg, 0.015 mmol) was added to a stirred solution of 203 (4.9 mg, 0.015 mmol) in 
MeOH (1.5 mL) at 50 °C. After 16 h, the crude reaction mixture was passed through a 
0.2 μm PTFE syringe filter, and then injected into a semipreparative HPLC column 
(Phenomenex Gemini RP-C18 column; 5 μ, 25 cm × 1 cm (40% ACN/H2O, 2.0 mL/min) 
to give 226 (9.5 mg, 95%) as a mixture of several inseparable regioisomers (tR = 8.5–5.0 
min): UV λmax 273 nm (ε 12 550); 1H NMR (DMSO-d6) δ 1.64-1.81 (m, 2H, NH2), 2.11-
2.15 (m, 1H, H2'), 2.15-2.30 (m, 2H, CH2CO), 2.60-2.79 (m, 2H, CH2NH2), 3.34-3.95 
(m, 4H, H3', H4', H5' & H5"), 4.51-4.60 (m, 2H, CH2), 4.91 (dd, J = 5.8, 2.3 Hz, 1H, 
H2'), 5.18-5.48 (m, 3H, 3 x OH), 5.74 (d, J = 6.7 Hz, 0.5H, H1'), 5.76 (d, J =6.2 Hz, 
0.5H, H1'), 5.94 (br d, J = 15.8 Hz, 1H, CH2), 6.12 (br d, J = 16.4 Hz, 1H, CH2), (6.86-
7.84 (m, 8H, Har), 8.4 (s, 0.5H, H2), 7.94 (s, 0.5H, H2); HRMS (ESI+) m/z calcd 
C28H29N10O4 (M+H)+: 569.2368, found: 569.2411. 
8-(1,2,3-Triazol-1H-yl)adenosine-MFCO adduct (228). Cyclooctyne 227 (6.25 
mg, 0.02 mmol) was added to a stirred solution of 200 (6.25 mg, 0.02 mmol) in MeOH (1 
mL) at ambient temperature. After 16 h, the volatiles were evaporated in vacuo to give 
cycloadduct 228 (1:1; 12.3 mg, 98%) as a clear oil: UV λmax 271 nm (ε 16 400), λmin 242 
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nm (ε 8000); 1H NMR (DMSO-d6/D2O) δ 1.43-1.50 (m, 6H, 3 x CH2), 1.56-1.67 (m, 4H, 
2 x CH2), 1.67-1.75 (m, 2H, CH2), 2.23-2.34 (m, 2H, CH2), 2.54-2.60 (m, 2H, CH2), 
2.60-2.67 (m, 2H, CH2), 2.76-2.82 (br s, 4H, 2 x CH2), 3.04-3.13 (m, 2H, CH2), 3.45 
("dd", J = , 10.8, 2.3 Hz, 1H, H5'), 3.51 ("dd", J = 2.2 Hz, 10.9 Hz, 1H, H5''), 3.87-3.90 
(m, 0.5H, H4'), 3.91-3.95 (m, 0.5H, H4'), 4.03 (m, 0.5H, H3'), 4.09 (m, 0.5H, H3'), 4.97 
(t, J = 4.9 Hz, 0.5H, H2'), 4.98 (t, J = 5.1 Hz, 0.5H, H2'), 5.27 (d, J = 7.0 Hz, 0.5 H, 
H1'),  5.28 (d, J = 7.1 Hz, 0.5 H, H1'), 8.27 (s, 0.5H, H2), 8.28 (s, 0.5H, H2); HRMS 
(ESI+) m/z calcd C29H37FN10NaO9 (M+Na)+: 711.2621, found: 711.2543.  
2-(1,2,3-Triazol-1H-yl)adenosine-OCT adduct (234). Cyclooctyne 217 (4.7:1 
exo-endo mixture; 3.13 mg, 0.020 mmol) was added to a stirred solution of 2-
azidoadenosine104 201 (6.25 mg, 0.020 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at 
ambient temperature. After 2 h, the volatiles were evaporated in vacuo to give 234 (9.3 
mg, 100%) as a white solid: UV λmax 261 nm (ε 19 100),  λmin 246 nm (ε 16 600); 1H 
NMR (DMSO-d6) δ 0.81-0.89 (m, 2H, 2 x Hγ), 0.94-1.04 (m, 1H, CH cyclopropyl), 1.56-
1.72 (m, 2H, 2 x Hβ), 2.06-2.22 (m, 2 H, 2 x Hβ), 2.81-2.90 (m, 1H, Hα), 2.99-3.14 (m, 
2H, 2 x Hα), 3.15-3.19 (m, 1H, Hα), 3.44-3.58 (m, 3H, H5' & CH2), 3.59-3.69 (m, 1H, 
H5''), 4.11-4.16 (m, 1H, H4'), 4.35 (t, J = 5.0 Hz, 1H, H3'), 4.59 ("quin", J = 6.0 Hz, 1H, 
H2'), 4.99-5.04 (m, 1H, OH), 5.21 (d, J = 4.9 Hz, 1H, OH), 5.45-5.53 (m, 2H, 2 x OH), 
5.89 (d, J = 5.8 Hz, 1H, H1'), 7.89 (br s, 2H, NH2), 8.52 (s, 1H, H8); HRMS (ESI+) m/z 
calcd C20H27N9O5 (M+H)+: 459.2099, found: 459.2098.  
2-(1,2,3-Triazol-1H-yl)adenosine-DBCO adduct (235). Cyclooctyne 223 (9.67 
mg, 0.035 mmol) was added to a stirred solution of 201 (10.93 mg, 0.035 mmol) in 
MeOH (1 mL) at ambient temperature. After 16 h, the volatiles were evaporated in vacuo 
116 
 
and the residue was passed through a 0.2 μm PTFE syringe filter, and then purified on the 
semipreparative HPLC column (17% ACN/H2O, 2.0 mL/min) to give 235 (17.5 mg, 
85%) as a mixture of several inseparable isomers (tR = 13.0–16.2 min): UV λmax 263 nm 
(ε 16 400), λsh 274 nm (ε 9 600), λmin 253 nm (ε 15 200);  Two major isomers (~85-90% 
of total isomeric composition) had: 1H NMR (DMSO-d6) δ 1.58-1.62 (m, 2H, NH2), 2.03-
2.09 (m, 2H, CH2CO), 2.57-2.72 (m, 2H, CH2NH2), 3.49-3.50 (m, 1H, H5'), 3.69 (dd, J = 
11.8 Hz & 3.3 Hz, 1H, H5"), 3.83-3.94 (m, 1H, H4'), 4.07-4.16 (m, 1H, H3'),  4.38 (t, J = 
5.1 Hz, 0.5H, H2'), 4.44 (t, J = 5.0 Hz, 0.5H, H2'), 4.53 ("dm", J = 17.0 Hz, 1H, CH2), 
4.86-5.47 (m, 3H, 3 x OH), 5.67 (d, J = 7.1 Hz, 0.5H, H1'), 5.82 (d, J = 7.2 Hz, 0.5H, 
H1'), 5.96 (br d, J = 19.7 Hz, 2H, CH2), 7.06-7.52 (m, 8H, Har), 8.54 (s, 0.5H, H8), 8.55 
(s, 0.5H, H8); HRMS (ESI+) m/z calcd C28H29N10O5 (M+H)+: 585.2317, found: 585.2318.  
5-(1,2,3-Triazol-1H-yl)uridine-OCT adduct (244). Cyclooctyne 217 (4.0 mg, 
0.025 mmol) was added to a stirred solution of 5-azidouridine 202 (7.3 mg, 0.025 mmol) 
in a mixture of ACN/H2O (3:1, 1 mL) at ambient temperature. After 15 min, the volatiles 
were evaporated in vacuo, and the oily residue was passed through a 0.2 μm PTFE 
syringe filter, and then purified on the semipreparative HPLC column (20% ACN/H2O, 
2.0 mL/min; tR = 5.2 – 8.0 min) to give 244 (6.2 mg, 77%) as a 1:1 mixture of isomers: 
UV λmax 270 nm (ε 10 100) λmin 248 nm (ε 6 800); 1H NMR (DMSO-d6) δ 0.85-0.93 (m, 
2H, 2 x Hγ), 0.95-1.02 (m, 1H, CH cyclopropyl), 1.46-1.56 (m, 2H, 2 x Hβ), 1.99-2.14 
(m, 2H, 2 x Hβ), 2.72-2.83 (m, 2H, 2 x Hα), 3.00-3.04 (m, 0.5H, Hα), 3.05-3.08 (m, 
0.5H, Hα), 3.16-3.18 (d, J = 5.2 Hz, 1H, Hα), 3.50 (dd, J = 2.5, 12.0 Hz, 1H, H5'), 3.59-
3.62 (m, 1H, H5''), 3.85-3.89 (m, 1H, H4'), 3.95-4.01 (m, 1H, H3'), 4.10 ("q", J = 4.6 Hz, 
1H, H2'), 4.36 (t, J = 4.9Hz, 1H, OH), 5.09-5.14 (m, 2H, 2 x OH), 5.51-5.55 (m, 1H, 
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OH), 5.78 (d, J = 4.0 Hz, 0.5H, H1'), 5.79 (d, J = 3.9 Hz, 0.5H, H1'), 8.52 (s, 0.5H, H2), 
8.53 (s, 0.5H, H2); HRMS (ESI+) m/z calcd C19H27N5O7 (M+H)+: 436.1827, found: 
436.1829.  
5-(1,2,3-Triazol-1H-yl)uridine-biotin adduct (245). Cyclooctyne 218 (11.0 mg, 
0.02 mmol) was added to a stirred solution of 5-azidouridine 202 (5.6 mg, 0.02 mmol) in 
a mixture of ACN/H2O (3:1, 1 mL) at ambient temperature. After 3 min, the volatiles 
were evaporated in vacuo to give cycloadduct 245 (16.0 mg, 98%) as a white solid: 
HRMS (ESI+) m/z calcd C36H53N9O12S (M+H)+: 836.3607, found: 836.3562. 
2'-Deoxy-8-(1,2,3-triazol-1H-yl)uridine-OCT adduct (246). Cyclooctyne 217 
(4.7:1 exo-endo mixture; 14.3 mg, 0.1 mmol) was added to a stirred solution of 242255 
(26.7 mg, 0.1 mmol) in a mixture of ACN/H2O/MeOH (3:1:1, 1 mL) at ambient 
temperature. After 15 min, the volatiles were evaporated in vacuo to give cycloadduct 
246 as mixture of isomers (~1:1; 15.3 mg, 100%) as a white solid: 1H NMR (DMSO-d6) 
δ 0.83-0.94 (m, 2H, 2 x Hγ), 0.95-1.05 (m, 1H, CH cyclopropyl), 1.42-1.59 (m, 2H, 2 x 
Hβ), 1.98-2.14 (m, 2H, 2 x Hβ), 2.20 ("t", J = 5.2 Hz, 2H, H2' & H2''), 2.46-2.56 (m, 1H, 
Hα), 2.70-2.83 (m, 2H, 2 x Hα), 3.00-3.05 (m, 0.5H, Hα), 3.05-3.09 (m, 0.5H, Hα), 3.44-
3.54 (m, 3H, H5' & CH2), 3.54-3.61 (m, 1H, H5"), 3.80 (q, J = 3.2 Hz, 1H, H4'), 4.17-
4.26 (m, 1H, H3'), 4.34 (m, 1H, OH), 5.02 (m, 1H, OH), 5.28 (m, 1H, OH), 6.15 (t, J = 
6.3 Hz, 0.5H, H1'), 6.16 (t, J = 6.3 Hz, 0.5H, H1'), 8.43 (s, 0.5H, H6), 8.44 (s, 0.5H, H6); 
HRMS (ESI+) m/z calcd C19H26N5O6 (M+H)+: 420.1878, found: 420.1878. 
5-(1,2,3-Triazol-1H-yl)uridine-DBCO adduct (247). Cyclooctyne 223 (5.6 mg, 
0.02 mmol) was added to a stirred solution of 202 (5.5 mg, 0.02 mmol) in MeOH (1 mL) 
at ambient temperature. After 15 min, the volatiles were evaporated in vacuo and the 
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residue was passed through a 0.2 μm PTFE syringe filter, and then injected into a 
semipreparative HPLC column (40% ACN/H2O, 1.0 mL/min; tR = 7.0–12.0 min) to give 
247 as an inseparable mixture of isomers (5.1 mg, 77%): UV λmax 276 nm (ε 7300), 291 
nm (ε 7100),  λsh 309 nm  (ε 5400),  λmin 265 nm (ε 6750), 283 nm (ε 7000),  303 nm (ε 
5000); HRMS (ESI+) m/z calcd C27H28N9O7 (M+H)+: 562.2045, found: 526.2040. 
5-(1,2,3-Triazol-1H-yl)uridine-MFCO adduct (248). Cyclooctyne 227 (7.6 mg, 
0.02 mmol) was added to a stirred solution of 5-azidouridine 202 (5.6 mg, 0.02 mmol) in 
MeOH (1 mL) at ambient temperature. After 12 min, the volatiles were evaporated in 
vacuo to give complete conversion to cycloadduct 248 as mixture of regioisomers (1:1; 
12.9 mg, 100%) as a white solid: UV λmax 269 nm (ε 7100), λmin 244 nm (ε 5000);  1H 
NMR (DMSO-d6) δ 1.40-1.50 (m, 6H, 3 x CH2), 1.73-1.81 (m, 2H, CH2), 2.27-2.34 (m, 
2H, CH2), 1.57-1.67 (m, 6H, 3 x CH2), 2.48-2.53 (m, 2H, CH2), 2.62-2.69 (m, 2H, CH2), 
2.78-2.86 (s, 4H, 2 x CH2), 3.01-3.13 (m, 2H, CH2), 3.47-3.54 (m, 1H, H5'), 3.60-3.65 
(m, 1H, H5"), 3.94-3.99 (m, 1H, H4'), 4.08-4.15 (m, 1H, H3'), 4.27-4.36 (m, 1H, H2'), 
5.06-5.11 (m, 2H, OH (2') & OH (3')), 5.51 (t, J = 6.7 Hz, 1H, OH (5')), 5.78 (d, J = 4.9 
Hz, 0.5 H, H1'),  5.79 (d, J = 4.6 Hz, 0.5 H, H1'), 8.57 (s, 1H, H6); HRMS (ESI+) m/z 
calcd C28H36FN7O11 (M+H)+: 666.2530, found: 666.2518. 
8-(1,2,3-Triazol-1H-yl)adenosine-OCT adduct triphosphate (230). 
Cyclooctyne 217 (5.6 mg, 0.01 mmol) was added to a stirred solution of 8-
azidoadenosine 5'-triphosphate tetralithium salt 229 (3.2 mg, 0.01 mmol) in a mixture of 
ACN/H2O (3:1, 1 mL) at ambient temperature. After 2 h, the volatiles were evaporated in 
vacuo to give 230 (3.2 mg, 92%) as a 1:1 mixture of regioisomers: 1H NMR (ACN-
d3/D2O) δ 0.80-0.88 (m, 2H, 2 x Hγ), 0.95-1.06 (m, 1H, CH cyclopropyl), 1.46-1.6 (m, 
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2H, 2 x Hβ),  2.06-2.28 (m, 2H, 2 x Hβ), 2.62-2.74 (m, 1H, Hα), 2.82-3.00 (m, 2H, 2 x 
Hα), 3.11-3.21 (m, 1H, Hα), 3.56-3.64 (m, 4H, H5', H5'' & CH2), 4.17-4.32 (m, 2H, H3' 
& H4'), 4.89 (t, J = 5.8 Hz, 0.5H, H2'), 4.97 (t. J = 5.7 Hz, 0.5H, H2'), 5.47 (d, J = 5.6 
Hz, 0.5H, H1'), 5.51 (d, J = 5.5 Hz, 0.5H, H1'), 8.32 (s, 0.5H, H2), 8.33 (s, 0.5H, H2); 
HRMS (ESI-) m/z calcd C20H28N8O14P3 (M+H)- 697.0943, found: 697.0962. 
4.4  NMR Kinetic Analysis of Selected SPAAC Reactions 
General Procedures. Kinetic data for the reactions between azides 200 or 229 and 
cyclooctyne 229 were acquired by 1H NMR at ambient temperature using a 400 MHz 
Bruker NMR. A 23 mM solution of azide 200 or 6 mM solution of azide 229 was each 
prepared in deuterated acetonitrile (CD3CN) and water (D2O) (3:1, v/v). For each 
experiment, three NMR tubes were prepared, each containing 700 µL of the azide 
solution. The solid cyclooctyne was added to one of the prepared NMR tubes and quickly 
shaken to dissolve. The resulting solution contained cyclooctyne and azide in a 1:1 ratio 
and was scanned every minute over 120 minutes. This procedure was repeated for each of 
the remaining prepared NMR tubes.  
For each of the azides tested, proton spectra showed formation of the desired click 
adducts without formation of any byproducts. The profile for the reaction was measured 
by integrating disappearance of the signal of H2 of substrate 200 or 229  at 8.07 ppm and 
appearance of H2 signal at 8.28 ppm for the product 203 or 230, respectively. Second 
order rate constants were calculated by plotting 1/[azide] as a function of time. The y-
intercept of each plot was set to 1/[starting azide concentration]. Plots show data 
collected to ~90% conversion to the triazole product 
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4.5 Synthesis of Phosphorylated Azides 
8-Azido-2'-deoxyadenoesine monophosphate (262). Azide 203 (5.0 mg, 0.017 
mmol), ATP (2 mM), DTT (2 mM), and BSA (0.5 mg/mL) were added to a solution of 
TRIS (50 mM, pH 7.6) containing KCl (100 mM) and MgCl2 (5 mM) for a final volume 
of 6 mL. The reaction was initiated by the addition of 6 x His -HdCK (1.33 mg/mL) and 
incubated at 37 °C. After 45 min, the reaction was quenched by cooling for 10 min at 0 
°C and then applied onto a DEAE Sephadex A-25 column (10 mL, 1 × 5.0 cm for a 17 
μmol synthesis). The column was eluted using a linear gradient of 0.1 – 0.4 M 
triethylammonium bicarbonate (TEAB) pH 7.5 in dH2O. The fractions eluting at 0.2 M 
TEAB were pooled together. Excess TEAB was removed with repeated cycles of dilution 
and concentration in vacuo from a 1:1 mixture of water and ethanol to give 262 as a 
triethylammonium salt: 1H NMR (D2O) δ 2.26 (dd, J = 14.0 Hz, 6.0 Hz, 1H, H2'), 2.76-
2.83 (m, 1H, H2"), 3.02-3.09 (m, 2H, H5' & 5"), 4.03-4.09 (m, 1H, H4'), 4.23 (bs, 1H, 
H3'), 6.50 (dd, J = 9.3 Hz, 6.0 Hz, 1H, H1'), 8.06 (s, 1H, H2); 31P NMR (D2O) δ 3.48 (s); 
MS (ESI+) m/z 369 (M+H)+.  
8-Azido-2'-deoxyadenoesine diphosphate (266). Monophosphate 262 (2.0 mg, 
0.005 mmol) ATP (4 mM) and DTT (2 mM) were added to a solution of TRIS (50 mM 
pH 8.0) containing MgCl2 (5 mM) for a final volume of 6 mL. The reaction was initiated 
by the addition of Myokinase (S.A. 3400 units/mL) and incubated at 37 °C. After 45 min, 
the reaction was quenched by cooling for 10 min at 0 °C and then applied onto a DEAE 
Sephadex A-25 column (15 mL, 1 × 5.0 cm for a 5 μmol synthesis). The column was 
eluted using a linear gradient of 0.005 – 0.6 M triethylammonium bicarbonate (TEAB) 
pH 7.5 in dH2O. The fractions eluting at 0.4 M TEAB were pooled together. Excess 
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TEAB was removed with repeated cycles of dilution and concentration in vacuo from a 
1:1 mixture of water and ethanol to give 266 as a triethylammonium salt: 1H NMR (D2O) 
δ 2.30 (ddd, J =14.1 Hz, 6.2 Hz, 2.3 Hz, 1H, H2'), 2.75-2.81 (m, 1H, H2"), 4.21-4.38 (m, 
4H, H3',4',5',5"), 6.47 (dd, J = 8.7 Hz, 6.3 Hz, 1H, H1'), 8.06 (s, 1H, H2); 31P NMR [1H] 
(D2O) δ -11.02 (s), -7.40 (s). 
8-Azido-2'-deoxyadenoesine triphosphate (260). Diphosphate 266 (2.0 mg, 0.005 
mmol) and PEP (4 mM) were added to a solution of TRIS (50 mM pH 8.0) containing 
MgCl2 (5 mM) for a final volume of 6 mL. The reaction was initiated by the addition of 
Pyruvate Kinase (S.A. 3400 units/mL) and incubated at 37 °C. After 45 min, the reaction 
was quenched by cooling for 10 min at 0 °C and then applied onto a DEAE Sephadex A-
25 column (15 mL, 1 × 5.0 cm for a 5 μmol synthesis). The column was eluted using a 
linear gradient of 0.1 – 0.8 M triethylammonium bicarbonate (TEAB) pH 7.5 in dH2O. 
The fractions eluting at 0.6 M TEAB were pooled together. Excess TEAB was removed 
with repeated cycles of dilution and concentration in vacuo from a 1:1 mixture of water 
and ethanol to give 260 as a triethylammonium salt. 
4.6  Synthesis of Azido Modified α-Ketoglutarate 
(S)-2-Azidopentanedioic acid (305). Triflic azide preparation: A solution of 
sodium azide was prepared by dissolving sodium azide (890 mg, 13.73 mmole) in 
deionized water (3.0 mL) and CH2Cl2 (4.0 mL) in a Morton flask. This solution was 
cooled to 0 °C in an ice bath for 5 min. Triflyl anhydride (0.465 mL, 2.78 mmole) was 
added slowly with a syringe over 5 min with very vigorous stirring. This was allowed to 
stir as an emulsion for an additional 2 h. The mixture was placed in a separatory funnel 
and the organic layer was removed. The aqueous portion was washed with CH2Cl2 (2 x 
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20 mL). The organic fractions containing triflic azide were pooled, washed with NaHCO3 
and used directly without further purification. Diazo transfer reaction: α-Ketoglutarate 
304 (205 mg, 1.4 mmole) was combined with K2CO3 (289 mg, 2.1 mmole) and CuIISO4 
pentahydrate (4.0 mg, 14 µmole) in distilled water (4.5 mL) and MeOH (9 mL) The 
freshly prepared triflyl azide in CH2Cl2 was added and allowed to stir at ambient 
temperature and pressure overnight in a Morton flask. After 16h, the reaction had turned 
a bright blue color. The organic volatiles were evaporated in vacuo and the aqueous 
portion was diluted with H2O (25 mL) and acidified to pH 6 with conc. HCl (6M). The 
aqueous layer was washed four times with EtOAc to remove the sulfonamide byproduct. 
Then, the aqueous phase was once again acidified to pH 2 and the extracted with EtOAc 
(3 x 20 mL). These extracts were pooled together, dried with MgSO4 and evaporated to 
dryness to give 305299 (90 mg, 75%) as a pale oil: 1H NMR (D2O) δ 1.78-1.91 (m, 1H, 
H3), 1.95-2.06 (m, 1H, H3), 2.28-2.42 (m, 2H, H4), 4.09 (dd, J = 8.4 Hz, 5.0 Hz, 1H, 
H2).  
2-(1,2,3-Triazol-1H-yl)pentanedioic acid OCT adduct (306). Cyclooctyne 217 
(14.0 mg, 0.095 mmol) was added to a stirred solution of (S)-2-azidopentanedioic acid 
305 (15.0 mg, 0.087 mmol) in a mixture of ACN/H2O (3:1, 1 mL) at ambient 
temperature. After 6 h, the volatiles were evaporated in vacuo, the residue was taken up 
in CHCl3 and washed with H2O to give 306 (23.0 mg, 92%) in the aqueous layer: 1H 
NMR (DMSO) δ 0.74-0.84 (m, 2H, 2 x Hγ), 0.97 (quin, J = 16 Hz, 1H, CH cyclopropyl), 
1.46-1.64 (m, 2H, 2 x Hβ),  2.00-2.12 (m, 4H, 2 x Hβ & CH2(3)), 2.30-2.68 (m, 3H, 
CH(2) & CH2(4)), 2.54-2.68 (m, 1H, Hα), 2.72-2.90 (m, 2H, 2 x Hα), 2.92-3.02 (m, 1H, 
Hα), 3.47 (d, J = 7.9 Hz, 2H, CH2), 5.23 (bs, 1H, OH); MS (ESI-) m/z 324 (M+H)-. 
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4.7 Synthesis of SAM Analogues for TrmD 
5'-[(S)-[(3S)-3-Amino-3-carboxypropyl](E)-pent-2-en-4-ynylsulfonio]-5'-
deoxyadenosine (AdoEnYn) (310). Mesyl chloride (395 µL, 584 mg, 5.09 mmol) was 
added to a suspension of NaOH (222 mg, 5.57 mmol) in dichloromethane (6 mL), and the 
suspension was cooled to 0 °C. Freshly distilled (E)-pent-2- en-4-yn-1-ol 308 (380 mg, 
4.63 mmol) was added and the mixture stirred at ambient temperature overnight. After 16 
h, the crude reaction was washed with saturated NaHCO3 solution until the aqueous 
phase remained basic. Volatiles were evaporated in vacuo to give 309321 (600 mg, 81%) 
as a yellow oil. Mesylated alcohol 309 (600 mg, 3.75 mmol) was directly dissolved in a 
mixture (1 mL) of formic and acetic acid (1:1 v/v). The solution was added to S-adenosyl-
L-homocysteine 307 (10 mg, 26 µmol) and the reaction mixture stirred in the dark at 
ambient temperature overnight. After 14 h, the reaction was quenched with water (30 
mL) and the aqueous phase was extracted with diethylether (3 × 60 mL). The aqueous 
layer was passed through a 0.2 μm PTFE syringe filter, and then purified on the 
semipreparative HPLC column (5% ACN, 0.01% TFA/H2O, 1.0 mL/min) to give 310307 
as mixture of regioisomers (1:1; 1.0 mg, 9%) as a white solid (tR = 22.5–23.8 min): 1H 
NMR (D2O, pD 3.5): δ 2.38 (q, J = 5.9 Hz, 2H, CH2 β), 3.81-3.91 (m, 2H, H5' & H5"), 
3.56-3.68 (m, 2H, CH2 γ), 3.95-3.99 (m, 1H, Hα), 4.21 (d, J = 7.6Hz, 0.5H, H1"), 4.25 
(d, J = 7.6Hz, 0.5H, H1"), 4.40-4.52 (m, 1H, H4'), 4.56 (t, J = 5.9 Hz, 0.5H, H3'), 4.65 (t, 
J = 6.0 Hz, 0.5H, H3'), 4.78-4.85 (m, 1H, H2'), 5.65 (dd, J = 13.8 Hz, 2.2 Hz, 0.5H, H3"), 
5.85 (dd, J = 14.2 Hz, 2.3 Hz, 0.5H, H3"), 5.94-6.04 (m, 0.5H, H2"), 6.05-6.11 (m, 1.5H, 
H1' & H2"), 8.36 (s, 1H, H2), 8.37 (s, 0.5H, H8), 8.39 (s, 0.5H, H8); MS (ESI+) m/z 450 
(M+H)+. 
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5'-S-Adenosyl-4-thiobutyric Acid Methyl Ester (314). γ-Thiobutyrolactone (35 
µL, 53 mg, 0.52 mmol) was added dropwise to a stirred solution of NaOMe in MeOH 
[prepared in situ by dissolving Na metal (13 mg, 0.56 mmol) in MeOH (3 mL) under N2 
for 15 min] at ambient temperature. The 5'-chloro-5'-deoxyadenosine322 313 (100 mg, 
0.35 mmol) was then added to the resulting solution was refluxed for 3 h. The reaction 
was then allowed to continue stirring overnight at room temperature. After 24 h, the 
additional amount of freshly prepared thiolate (thiolactone (23 µL, 35.7 mg, 0.35 mmol) 
and Na metal (8.6 mg, 0.37 mmol) in 0.5 mL MeOH) was added and refluxed was 
continued for another 2 h. The MeOH was evaporated and the crude materials was 
dissolved in EtOAc, washed twice with NaHCO3 then with dilute HCl and lastly with 
brine. The organic layer was dried with MgSO4 and evaporated to give thick yellow oil 
which was chromatographed (100% CHCl3 → 15% MeOH in CHCl3) to give 314323 (35 
mg, 27%) as a light yellow oil: 1H NMR δ 1.61-1.69 (m, 2H, H8',8"), 2.22 (t, J = 7.3 Hz, 
2H, H9',9"), 2.42 (m, 2H, H7',7"), 2.83 (dd, J = 14.5 Hz, 6.5 Hz, 1H, H5'),  2.91 (dd, J = 
14.5 Hz, 5.0 Hz, 1H, H5"), 3.54 (s, 3H, CH3), 4.23 (q, J = 4.5 Hz, 1H, H4'), 4.35 (t, J = 
6.0 Hz, 1H, H3'), 4.82 (t, J = 5.6 Hz, 1H, H2'), 5.98 (d, J = 4.9 Hz, 1H, H1'), 8.15 (s, 1H, 
H8), 8.26 (s, 1, H2). MS (ESI+) m/z 384 (M+H)+. 
5'-S-Adenosyl-4-thiobutyric Acid (315). NaOH (0.08 mmol, 160 µL of 0.5M 
NaOH solution) was added to a stirred solution of 314 (10.0 mg, 0.026 mmol) in MeOH 
(0.5 mL). The reaction was quenched after 2 h with 1M HCl and evaporated to give 
315323 (9 mg, 94%) as a clear oil: 1H NMR δ 1.64-1.71 (m, 2H, H8' & 8"), 2.11 (t, J = 7.6 
Hz, 2H, H9',9"), 2.44-2.51 (m, 2H, H7',7"), 2.86 (dd, J = 15.2 Hz, 6.5 Hz, 1H, H5'), 2.95 
(dd, J = 14.9 Hz, 4.7 Hz, 1H, H5"), 4.26 (q, J = 5.1 Hz, 1H, H4'), 4.36 (t, J = 5.1 Hz, 1H, 
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H3'), 4.80 (t, J = 5.1 Hz, 1H, H2'), 5.99 (d, J = 5.11 Hz, 1H, H1'), 8.15 (s, 1H, H2), 8.28 
(s, 1H, H8). MS (ESI+) m/z 369 (M+H)+. 
3'-Azido-5'-chloro-3',5'-dideoxyadenosine (320). 3'-Azido-3'-deoxyadenosine 
319324 (40 mg, 0.13 mmol) was added to a precooled solution of thionyl chloride (51 µL, 
92.8 mg, 0.78 mmol) in HMPA (4 mL). The reaction was allowed to stir at ambient 
temperature for 1.5 h and then quenched with water (1.5 mL) decolorizing the reaction. 
The reaction mixture was applied to a Dowex column (H+), washed with 2 column 
volumes of water and eluted with 2N aqueous NH4OH and 2N aqueous NH4OH/MeOH 
(v/v 1:1). The fractions that contained UV were collected and extracted with ethyl acetate, 
dried over sodium sulfate and evaporated to yield 320310 (40 mg, 95%) as a white solid: 
1H NMR δ 3.71 (dd, J = 11.8 Hz, 4.0 Hz, 1H,  H5"), 3.80 (dd, J = 11.8 Hz, 4.0 Hz, 1H,  
H5'),  4.12 ("q", J = 4.6 Hz, 1H, H4'), 4.21 (t, J = 4.3 Hz, 1H, H3'), 4.99 (t, J = 5.3 Hz, 
1H, H2'), 5.86 (d, J = 5.9 Hz, 1H, H1'), 8.05 (s, 1H, H2), 8.12 (s, 1H, H8),  
3'-Azido-3'-deoxy-5'-S-Adenosyl-D/L-Homocysteine (321).  D/L-Homocysteine 
(9.7 mg, 0.057 mmol), NaOH (2 mg, 0.054 mmol) and KI (4 mg, 0.024 mmol) were 
added to a suspension of 3'-azido-5'-chloro-3',5'-dideoxyadenosine 320310 in 1 mL 
deoxygenated water [which had been boiled for 1 hour and then quickly cooled]. The 
reaction was allowed to sir at 100 °C for 5 h and then immediately cooled in ice bath. The 
pH was adjusted to 3.5 with 1N HCl(aq) and then applied directly to a Dowex (NH4+) 
column, washed with 2 column volumes of water and eluted with 1N aqueous NH4OH. 
The fractions that contained UV were collected and evaporated yield 321 (2.0 mg, 10%) 
as an ivory oil. 1H NMR δ 1.99-2.14 (m, 3, H8', H8" & H9'), 2.61 (t, J = 7.3 Hz, 2H, H7' 
& H7"), 2.91-3.02 (m, 2H, H5' & H5"), 3.96-4.10 (m, 1H, H4'), 4.28 (q, J = 12.0 Hz, 1H, 
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H3'), 5.05 (q, J = 7.2 Hz, 1H, H2'), 5.99 (d, J = 3.8 Hz, 1H, H1'), 7.97 (s, 1, H2), 8.11 (s, 
1H, H8), MS (ESI+) m/z 410 (M+H)+. 
5'-Chloro-3'-(N-Boc-S-trityl-homocystylamino)-3',5'-dideoxyadenosine (324). 
N-Boc-S-trityl-homocysteine (61 mg, 0.13 mmol) was coevaporated 3 times with dry 
THF (2 mL) and then dissolved in dry THF (1.75 mL) at 0°C. HOBt (21 mg, 0.17 mmol) 
was added to this solution and allowed to stir at 0 °C for 10 min. Then DIC (26 µL, 0.17 
mmole) was added drop wise and again allowed to stir for 10 min at 0°C. 3'-azido-5'-
chloro-3',5'-dideoxyadenosine 320 (20 mg, 0.065 mmol) and n-Bu3P were added and the 
temperature was allowed to warm up to room temperature over 30 min. At 4 h, all 
starting material had been consumed so volatiles were evaporated to yield an oil which 
was dissolved in CHCl3 and washed with water and brine. The residue was purified on 
silica gel column chromatography (EtOAc → 20% MeOH/EtOAc) to give 324 (6.1 mg, 
13%). 1H NMR δ 0.78-0.89 (m, 15H, t-Bu), 1.55-1.97 (m, 2H, CH2 β), 2.19-2.25 (m, 2, 
CH2 γ), 3.72-3.80 (m, 2H, H5' & H5"), 4.00 (q, J = 9.2 Hz, 1H, H4'), 4.21 (t, J = 3.2, 1H, 
Hα), 4.50-4.58 (m, 1H, H3'), 4.76-4.81 (m, 1H, H2'), 5.86 (d, J = 2 Hz, 1H, H1'), 6.23 
(bs, 2H, NH2), 6.81 (d, J = 3 Hz, 1H, NH), 8.05 (s, 1H, H8), 8.17 (s, 1H, H2). MS (ESI+) 
m/z 744 (M+H)+.  
4.8 Biological Evaluation of Azido Nucleosides and Click Adducts 
4.8.1 Parallel Artificial Membrane Permeability Assay (PAMPA) 
Permeability Measurements Typical Procedure: Parallel artificial membrane 
permeability assay (PAMPA) was used to determine effective permeability coefficients 
Pe (centimeters per second), in a 96-well microtiter filter plates, on polycarbonate filter of 
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.45 μm pore size, 10 μm thickness (Millipore AG, Volketswil, Switzerland), according to 
the procedure of Wohnsland and Faller.325  
Each well was coated with 15 μL of lecitin (1% or 4% in dodecane solution) for 5 
minutes avoiding pipette tip contact with the membrane. Each compound, dissolved in 
5% DMSO in PBS solution (concentration of 75 µM and 150 µM) was tested at least in 
triplicate. The compound containing solutions (300 µL each) was added to each well of 
the donor plate. Aqueous buffer (PBS) (300 µL) was added to each well of the acceptor 
plate and then the donor plate was placed upon the acceptor plate. The resulting chamber 
was incubated at room temperature for 16 h at ambient temperature under gentle shaking. 
After incubation, it was carefully disassembled and each well of the acceptor plate was 
analyzed using UV-Vis for compound concentration. A solution of each compound at its 
theoretical equilibrium (i.e., the resulting concentration of the donor and acceptor phases 
were simply combined) was similarly analyzed. The effective permeability (Log Pe) was 
calculated from the equation as reported by Faller et al.325 
4.8.2 MTT Assay 
MTT Typical Procedure: MCF-7 cells were seeded in 96-well plates at a density of 
1x104 cells/well and treated with different concentrations of azides 2 or 21 and 
cyclooctyne 5 for 24 h at 37 °C in a 5% CO2 incubator. Methylthiazoletetrazolium (MTT) 
solution (5 mg/ml) was added to the assay mixture and incubated for 4 h. The culture 
media was removed prior to addition of DMSO.  The optical density of the solution was 
measured at 595 nm, using an absorbance microplate reader (Bio-Tek). Cells without the 
treatment of the compounds were used as the control. The cell viability percentage was 
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calculated by the following formula: Cell viability percentage (%) = OD sample/OD 
control × 100% 
4.8.3 Fluorescent Cell Microscopy Studies  
Fluorescent Spectroscopy Typical Procedure: The MCF-7 cells (5 × 105 cells/mL) 
were seeded in an eight chambered coverglass system (1.5 German borosilicate 
coverglass, Lab-Tek II) and incubated at 37 °C overnight in Dulbecco’s modified Eagle’s 
medium (DMEM/F12 (1:1) 1X, 1.5 ml) containing 5% fetal bovine serum (FBS). The 
media was removed and reduced serum medium (OPTI-MEM I, 1X, Gibco, Invitrogen) 
was added to the cells and allowed to incubate at 37 °C for 3 h.  
The 8-azido-9-(β-D-arabinofuranosyl)adenine 2 in the reduced serum medium (1 µM) 
was added to the cells. After 4h, the cells were washed three times with fresh 
DMEM/F12 (1:1) 1X media to remove any azide from the exterior portions of the cells. 
The cyclooctyne reagent 5 in the reduced serum medium (1 µM) was then added to the 
the cells and incubated at 37 °C for 16 h. The cells were then washed three times with 
fresh DMEM/F12 (1:1) 1X media to remove any click adduct from the exterior portions 
of the cells and then observed with a DLITE-microscope (Fisher Scientific) using 
excitation and absorbance filters were 360/40 and 470/40 nm, respectively. 
In the first negative control, the MCF-7 cells were just incubated with azide 2 without 
the cyclooctyne reagent added. In the second negative control, the MCF-7 cells were just 
incubated with cyclooctyne 5 without the azide 2. Also, in the positive control the cells 
were treated with click adduct (e.g., 11) dissolved in culture media. We used 0.1% trypan 
blue in the culture media before imaging the cells in DV ELITE microscope. 
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Note: In parallel experiments Lipofectamine LTX was used as liposome carrier.  
4.9  Photophysical Screening and Evaluation of Triazole Adducts 
4.9.1 Photophysical Characterization 
The fluorescent properties of the triazole products were determined using samples 
of varying concentration but whose absorbance at the excitation wavelength did not 
exceed 0.1 absorbance units. For determination of ΦF the absorbance was kept below 
0.06 and quinine sulfate in 100mM sulfuric acid was used as reference standard (ΦF = 
0.55).326 All samples were prepared in HPLC grade MeOH, DMSO or 50mM phosphate 
buffer, and placed in a 2 x 10 mm quartz cuvette at 18 °C. Absorption spectra were 
measured using a single beam UV–Vis spectrophotometer (Cary 50, Varian). Steady-state 
excitation and emission spectra were measured on a PC1 spectrofluorometer with 
bandwidth and slit width for excitation/emission set at 2 nm.  Frequency-domain 
fluorescence lifetime measurements were performed using a ChronosFD 
spectrofluorometer. Samples were excited with a frequency modulated 280 nm LED and 
emission was collected using a 305 nm long pass filters (Andover); 2,5-Diphenyloxazole 
(PPO) solubilized in ethanol was used as a lifetime reference (τ =1.4 ns).327 Modulation-
phase data were fitted by a multiple-exponential decay model using GlobalsWE software 
and the residual and χ2 parameter was used as criterion for goodness of fit. 
4.9.2 Fluorescent Lifetime Imaging Microscopy 
Typical Procedure: Synthetically prepared triazole adduct 8, 20 or 23 as well as 
in vivo generated 8 [0.5 mL of 1 µM solution in DMEM/F12 (1:1) 1X media] were added 
to MCF-7 cells (~50% cell confluency) cultured on slides mounted with 1-tissue culture 
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well. After 24 h, the cells were washed twice with fresh (DMEM/F12 (1:1) 1X, 0.5 ml). 
The cells were then imaged at ambient temperature in fresh DMEM/F12 (~0.2 mL). Ex 
vivo lifetime measurements were acquired using a custom-assembled frequency-domain 
upright FLIM system from Intelligent Imaging Innovations Inc. (3i). A continuous–wave 
excitation source (488 nm Argon laser) was modulated by a Pockels cell electro-optic 
modulator, which was synchronized with a Lambert Instruments II18MD gated image 
intensifier and CoolSnap EZ camera. A Yokogawa CSU-X1 spinning disk provided 
confocal scanning for fast image acquisition. A Zeiss W Plan-Apochromat 63x (n.a. 1.0) 
water-immersion objective lens and a Semrock 520 emission filters with a Semrock Di10 
T488/568 diochroic were also used. Image intensification was maintained at 2800 units 
across all experiments. Exposure times were set to acquire enough signal to span 
approximately 75% of the CCD’s dynamic range, however this time was never extended 
to more than 40 seconds (as such samples typically have low signal-to-noise. System 
calibration was performed with the fluorescent dye, 1-hydroxypyrene-3,6,8-trisulfonate 
(HPTS), in solution (PBS at pH 7.5) for a standard lifetime of 5.4 ns. We found HPTS to 
be a reliable standard and superior to fluorescein, owing to its greater stability over time 
and pH shifts. 
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5 Conclusion 
In this dissertation, I have developed a protocol for the efficient strain promoted 
click chemistry of 2- or 8-azidoadenine and 5-azidouracil nucleosides as well as 8-
azidoadenosine triphosphate with various cyclooctynes. The reactions were performed in 
aqueous solution at ambient temperature without the assistance of copper and/or 
microwave heating. These triazole analogues were designed to have fluorescent, light-up, 
properties and were utilized for direct fluorescent imaging in living cells. As analogues of 
natural nucleosides, the synthesized click adducts are less likely to result in undue 
cellular stress and allow for a dynamic real-time view inside the cell.  
The azido nucleoside precursors were prepared either by substitution (e.g., 200, 
214-216) or diazo transfer (e.g., 202 and 243). These azido purine and pyrimidine 
modified nucleosides underwent stain promoted click chemistry (SPAAC) with several 
different cyclooctynes including some modified with fused cyclopropyl cyclooctyne (e.g., 
217 and 218), dibenzylcyclooctyne (e.g., 223) or monofluorocyclooctyne (e.g., 227) to 
produce triazole click products functionalized with hydroxyl, amino, N-
hydroxysuccinimide, or biotin moieties. Photophysical studies of the triazole adducts 
synthesized demonstrated complex fluorescence decay lifetimes with at least two or three 
lifetime components.  
The synthesized triazole adducts induced fluorescent properties which were used 
for direct imaging in MCF-7 cancer cells without the need for traditional fluorogenic 
reporters. Thus, the viability of these click reactions to produce fluorescent nucleoside 
analogues was demonstrated inside living cancer cells. From a cell cytotoxicity assay 
(MTT), it was determined that a 1 µM dosage of azides 202 and 214 were non-toxic. We 
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utilized this dosage for subsequent fluorescent studies. Additionally, a parallel artificial 
membrane (PAMPA) was used to predict the passive cellular permeability of selected 
azides and triazole adducts, which demonstrated that approximately 20% of each of the 
compounds tested passively permeated in through the cellular membrane.  
Fluorescence at the lower concentrations without the aid of liposome delivery was 
localized to the nucleus. Thus, fluorescence lifetime imaging microscopy (FD-FLIM) was 
used to determine the lifetime of each fluorophore from the fluorescent signal localized in 
the cellular nuclei using frequency-domain The observed FLIM values for the click 
adducts 234 and 244 were similar to those obtained through spectroscopic methods; 
however, the value found for 219 was much higher in vivo than that found in vitro.  The 
discrepancy between fluorescence lifetimes in vitro and within living cells can be 
attributed to different solvent conditions. Furthermore, the intranuclear solvent may exist 
at a higher or lower pH or π-orbital stacking may occur.  
The present in situ click chemistry drug delivery system represents a novel 
theranostics approach wherein both a therapeutic effect and drug uptake-related imaging 
information may be produced and readily monitored at the cellular level. The long-term 
implications of this in situ click chemistry drug delivery strategy embodied in the 
synthesized click substrates could allow for a more precise monitoring of dosage levels as 
well as an improved understanding of cellular uptake. It is also noteworthy that our 
nucleobase-derived triazole adducts can be visualized using fluorescent microscopy and 
FLIM without reliance on auxiliary fluorescent reporters such as green-fluorescent 
protein328 or Alexa Fluor.329 
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Through the screening and evaluation of a library of numerous nucleoside 
analogues, I have demonstrated that 9-(2-deoxy-2-fluorob,D-arabinofuranosyl)adenine 
215 is more active against protozoan parasite T. vaginalis (IC50 0.09 µM) than the current 
FDA approved drug for treatment of trichomoniasis, metronidazole (IC50 0.72 μM). 
Furthermore, fluoro-arabinoadenosine 215 was also active against the metronidazole 
resistant strain of T. vaginalis ( IC50 0.21 µM), but shows no effect on non-infected 
mammalian cells. Further investigation of this compound may provide a basis for 
development of new drugs against this important human parasite. Tagging and 
subcellular localization studies using azido modified fluoro-arabinoadenosine 272 could 
provide insight into the cellular targets of fluoro-arabinoadenosine 215. 
An activated analogue of SAM with an EnYn group on the sulfur instead of a 
methyl was prepared. Ivestigation with the Trm1 enzyme showed that AdoEnYn 310 can 
inhibit AdoMet-dependent methylation of tRNA which indicates that it is a competitive 
inhibitor of the natural methyl donor, SAM. Furthermore, since the EnYn group was 
transferred from the sulfur on AdoEnYn 310 by methyltransferase Trm1 to guanosine on 
tRNA 311, it was determined that AdoEnYn can be incorporated into tRNA in place of 
AdoMet.  
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